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ABSTRACT 
The Effects of Arrhythmogenic Right Ventricular Cardiomyopathy-Causing Proteins  
on the Mechanical and Signaling Properties of Cardiac Myocytes 
Venkatesh Hariharan 
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by a high 
incidence of lethal ventricular arrhythmias, fibrofatty replacement of myocardium, and can 
account for up to 20% of sudden cardiac death (SCD) cases in the young. Typically involving 
autosomal dominant transmission, germline mutations in genes encoding desmosomal proteins 
have been identified as a cause of ARVC, although the pathogenesis of the disease is still 
unclear. While early detection and treatment can provide a normal life expectancy for the 
majority of patients, with less than 10% progressing to overt right ventricular failure, low genetic 
penetrance and epigenetic modifiers (such as endurance exercise) can make the condition 
difficult to diagnose. Addressing this clinical challenge requires a better understanding of the 
defective molecular mechanisms that underlie the disease. To that end, the goal of this 
dissertation is to provide insight into the effects of ARVC-causing mutant proteins on the 
mechanical and signaling properties of cardiac myocytes.  
Using elastography and histological techniques, we begin by characterizing the structural 
and mechanical properties of the native right ventricular myocardium, particularly the right 
ventricular apex (RVA). Because the RVA is a key site for development of arrhythmias and a 
potential pacing target, a careful characterization of its structure and mechanical properties are 
essential for understanding its role in cardiac physiology. In the first section of this dissertation, 
we perform a systematic analysis of the structural features and mechanical strains in the heart, 
focusing on the RVA region.  
 
More than half of ARVC patients exhibit one or more mutations in genes encoding 
desmosomal proteins. This has led many investigators to suggest that ARVC is a “disease of the 
desmosome” in which defective cell-cell adhesion plays a critical pathogenic role, although 
direct evidence for this hypothesis is lacking. To gain greater insights into potential mechanisms 
by which desmosomal mutations cause ARVC, we next characterize biomechanical properties 
and responses to shear stress (motivated by our results in the previous section) in neonatal rat 
ventricular myocytes expressing two distinct mutant forms of the desmosomal protein 
plakoglobin which have been linked to ARVC in patients. We show that ARVC-causing 
mutations in plakoglobin lead to altered cellular distribution of plakoglobin, without alterations 
in cell mechanical properties or certain early signaling pathways. 
The identification of defective molecular mechanisms that are common across ARVC-
patients remains a strategic area of research. Specifically, recent studies have investigated the 
mechanistic basis for different ARVC-causing mutations in hopes of identifying common defects 
in a signaling pathway – information that could be used to develop diagnostic tests or identify 
therapeutic targets. In the last section of this dissertation, we investigate the effects of mutant 
plakophilin-2 expression, and repeat key experiments performed in the previous section to 
identify common defects in mechanical and signaling properties. We identify a common, 
underlying defect in ARVC pathogenesis. Specifically, we show that disease-causing mutations 
across different desmosomal proteins can cause the cell to respond abnormally to mechanical 
shear stress with respect to plakoglobin trafficking.  
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3.2.5, the derived expression to calculate applied shear stress is directly proportional to the flow 
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Figure 3.3 – ARVC models express transgenic plakoglobin at endogenous levels: (A) V5 
immunostaining of control (non-transfected) myocytes (C) and myocytes transfected to express 
wild-type plakoglobin (WT PG), S39_K40insS (InsS PG), or 2057del2 PG.  No signal is seen in 
non-transfected control cells (thus demonstrating absence of non-specific binding). Normal 
junctional localization of V5 labeled protein is seen in cells transfected to express WT PG, InsS 
PG and 2057del2 PG mutants.   Cells transfected with 2057del2 PG also show nuclear 
localization of truncated 2057del2 plakoglobin.  (B) Immunostaining with an anti-plakoglobin 
antibody against an N-terminal epitope (which recognizes both endogenous and transfected 
forms of WT PG, InsS PG and 2057del2 PG) shows a similar pattern.   (C)  Immunoblot (left) 
using an N-terminal anti-plakoglobin antibody, with quantification (right) showing roughly 
equivalent amounts of endogenous plakoglobin and transgene plakoglobin in WT PG, InsS PG 
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plakoglobin band observed in the 2057del2 PG lane is explained by the truncation of the C-
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2057del2 mutation. (D) Quantification of cells transfected with a GFP virus to confirm 98.9 ± 
1.1% transfection efficiency (n=5). Scale bars = 20 μm.  
 
Figure 3.4 - Cell-cell adhesion strength and cell stiffness are unaffected by mutant plakoglobin:  
(A) Quantification of control and mutant plakoglobin-transfected cardiac myocyte monolayer 
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fragmentation in dispase assays before and after 1 or 3 minutes of agitation. Cardiac myocytes 
expressing mutant plakoglobin show no differences in cell-cell adhesion relative to WT PG 
(n=5).  (B) Quantification of cluster sizes in control and transfected cardiac myocytes in cell 
aggregate assays (n=3). Cardiac myocyte aggregates expressing mutant plakoglobin show no 
differences in aggregate fragmentation relative to WT PG. (C) Dispase assays in normal (non-
transfected) cardiac myocytes showing significant reduction in cell-cell adhesion in cells 
exposed to 1uM cytochalasin-D (n=5). (D) Dispase assays in normal (non-transfected) cardiac 
myocytes showing significant reduction in cell-cell adhesion in cells following siRNA knock-
down of endogenous plakoglobin (n=5).  Plakoglobin knock-down was confirmed by 
immunoblotting (inset), and quantified (right). (E) Quantification of apoptosis (percent TUNEL-
positive nuclei) in control (C) cells transfected with non-targeting siRNA, or siRNA targeting 
plakoglobin (n=6). Mechanical shear caused cells to shear off the glass slide, preventing 
quantification. (F) Dispase assays in normal (non-transfected) cardiac myocytes showing 
significant reduction in cell-cell adhesion in cells following siRNA knock-down of endogenous 
N-cadherin (Nc) (n=6).  N-cadherin knock-down was confirmed by immunoblotting (inset), and 
quantified (right). *p < 0.05; **p < 0.01 
 
Figure 3.5 – Shear-induced plakoglobin remodeling is reversibly altered in ARVC: (A) Immuno-
fluorescence images showing the distribution of plakoglobin (N-terminal antibody) in control (C) 
and transfected cardiac myocytes before (top) and after (middle) exposure to shear, and after 
treatment with SB216763 (SB2; bottom).  Control and WT PG cells show increased 
immunoreactive signal with junctional localization after shear, whereas cells expressing InsS PG 
or 2057del2 PG show no apparent increase in junctional signal after shear.  Treatment with the 
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drug restored the normal shear-induced increase in junctional signal in cells expressing mutant 
plakoglobin or plakophilin. (B) Quantification of junctional plakoglobin signal before and after 
shear in cells transfected to express mutant plakoglobin (n=5). (C) Quantification of junctional 
plakoglobin signal before and after shear in cells transfected to express mutant plakoglobin and 
treated with SB216763 (n=6). (D) Immunoblot using a N-terminal anti-plakoglobin antibody 
showing no overt changes in plakoglobin levels in cells expressing WT or 2057del2 PG (n=5) in 
response to shear or treatment with SB216763. Scale bars = 20 μm. *p< 0.05; ** p< 0.01   
 
Figure 3.6 - Shear-induced N-cadherin remodeling is reversibly altered in ARVC: (A) N-
cadherin immunofluorescence images showing the distribution of N-cadherin in control (C) and 
transfected cardiac myocytes before (top) and after (middle) exposure to shear, and after 
treatment with SB216763 (bottom).  As seen in Figure 3, control (non-transfected) cells and cells 
transfected to express wild-type plakoglobin (WT PG) show increased junctional signal for N-
cadherin after shear, whereas no shear-induced increase was seen in cells expressing mutant 
forms of plakoglobin.  Treatment with the drug restored the normal shear-induced increase in 
junctional signal in cells expressing mutant plakoglobin. (B) Quantification of junctional N-
cadherin signal before and after shear (n=5). (C) Quantification of junctional N-cadherin signal 
before and after shear in cardiac myocytes treated with SB216763 (n=5).  SB216763 restored the 
normal shear-induced increase in junctional N-cadherin signal.  (D) Dispase assay measurements 
in control cells (C) and cells expressing transgenic plakoglobin after exposure to mechanical 
shear stress (n=5).  Cardiac myocytes expressing mutant plakoglobin show no differences in cell-
cell adhesion as compared to control cells. (E) Cell stiffness measurements in control cells (C) 
and cells expressing wild type or mutant plakoglobin before and after exposure to mechanical 
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shear stress (n=4).  Cardiac myocytes expressing mutant plakoglobin show no differences in cell 
stiffness compared to control cells.  *p<0.05; **p<0.01 
 
Figure 3.7 - Cell viability, but not ERK phosphorylation, is altered by mutant plakoglobin 
expression: (A) Quantification of apoptosis (percent TUNEL-positive nuclei) in control (C) cells 
and cells transfected to express wild-type or mutant forms of plakoglobin before and after 
exposure to shear (n=4).  Mechanical shear stress caused an increase in apoptosis in cells 
expressing 2057del2 PG.  (B)  Quantification of apoptosis (percent TUNEL-positive nuclei) in 
cells treated with SB216763 (SB2) before and after shear (n=3).  SB216763 prevented the shear-
induced increase in apoptosis in cells expressing 2057del2 PG.  (C) Representative immunoblot 
and quantitative data showing equivalent levels of phospho-ERK activation (P-ERK), with total 
ERK (T-ERK) as a loading control, in control cells (C) or cells transfected to express wild-type 
or mutant forms of plakoglobin (n=3). *p<0.05  
 
Figure 3.8 - GSK3 Suppression Does Not Mimic the Effects of SB216763: (A-B) Quantification 
of junctional plakoglobin signal before and after shear in cells treated with (A) non-targeting 
(n=3) or (B) GSK3 siRNA (n=3).  Knockdown of GSK3 did not restore the normal shear-
induced increase in junctional signal in cells expressing InsS or NX plakoglobin. (C) Scatter 
plots from microarray data analysis showing differential gene expression when comparing NX 
cells exposed to shear stress, treated with SB216763, or both (n=3). (D) Immunoblots using anti-
Rnd1 (top), anti-Isg15 (middle) or anti-GAPDH (bottom) antibodies in WT and NX cells 
exposed to shear stress, treated with SB216763, or both. Isg15 and Rnd1 were targets identified 




Figure 4.1 – ARVC models express transgenic plakophilin: (A) V5 Stain on control (C), wild-
type plakophilin (WT PKP), and mutant plakophilin (1851del123 PKP) transfected myocytes.  
Normal junctional localization is seen in WT PKP transfected cells. No junctional signal is 
observed in cells expressing 1851del123 PKP. (B) Immunostaining with an anti-plakophilin-2 
antibody against a C-terminal epitope (which recognizes both endogenous and transfected forms 
of WT PKP and 1851del123 PKP. (C) Immunoblots using anti-V5 (top), anti-C-terminal 
plakophilin (middle) and anti-GAPDH (bottom) antibodies. V5 bands in the WT PKP and 
1851del123 PKP lysates confirm successful transfection. The relatively similar size between 
exogenous and endogenous plakophilin prevented detection of discrete bands using the anti-C-
terminal plakophilin antibody. (D) Quantification of cells transfected with a GFP virus to 
confirm 97.9 ± 0.2% transfection efficiency (n=3). Scale bars = 20 μm. 
 
Figure 4.2 - Cell-cell adhesion strength and stiffness are unaffected by mutant plakophilin 
expression: (A) Quantification of control and mutant plakophilin transfected cardiac myocyte 
monolayer fragmentation in dispase assays before and after 1 or 3 minutes of agitation. Similar 
to myocytes expressing mutant plakoglobin, cardiac myocytes expressing mutant plakophilin-2 
(n=6) also show no differences in cell-cell adhesion relative to WT PKP (n=4), suggesting the 
effect does not depend on which desmosomal protein is being mutated. (B) Dispase assays in 
normal (non-transfected) cardiac myocytes showing significant reduction in cell-cell adhesion in 
cells following siRNA knock-down of endogenous plakophilin-2 (n=5).  Plakophilin-2 knock-
down was confirmed by immunoblotting (inset), and quantified (right). (C) Quantification of 
apoptosis (percent TUNEL-positive nuclei) in control cells transfected with non-targeting 
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siRNA, or siRNA targeting plakophilin (n=6). (D) Cell stiffness measurements in control cells 
(C) and cells expressing wild type or mutant plakophilin before and after exposure to mechanical 
shear stress (n=3).  Cardiac myocytes expressing mutant plakophilin show no differences in cell 
stiffness compared to control cells.  *p<0.05; **p<0.01 
 
Figure 4.3 – Shear-induced plakoglobin and plakophilin localization are reversibly altered in 
pkp-model ARVC cells: (A) Immunofluorescence images showing the distribution of plakophilin 
(C-terminal antibody) in control (C) and transfected cardiac myocytes before (top) and after 
(middle) exposure to shear, and after treatment with SB216763 (SB2; bottom).  Control and WT 
PKP cells show increased immunoreactive signal with junctional localization after shear, 
whereas cells expressing 1851del123 PKP show no apparent increase in junctional signal after 
shear.  Treatment with the drug restored the normal shear-induced increase of in junctional signal 
in cells expressing mutant plakophilin. (B-C) Quantification of junctional plakophilin signal 
before and after shear in (B) untreated (n=3) or (C) SB216763 treated (n=3) cells transfected 
with wild-type or mutant plakophilin.  (D-E) Quantification of junctional plakoglobin signal 
before and after shear in (D) untreated (n=4) or (E) SB216763 treated (n=4) cells transfected 
with wild-type or mutant plakophilin. (F-G) Quantification of junctional plakophilin signal 
before and after shear in (F) untreated (n=3) or (G) SB216763 treated (n=3) cells transfected 
with wild-type or mutant plakophilin.*p< 0.05; **p<0.01 
 
Figure 4.4 – Plakophilin Knockdown Alters Plakoglobin Remodeling, But Not Vice Versa: (A-
B) Quantification of junctional plakophilin signal before and after shear in (B) untreated (n=3) or 
(C) SB216763 treated (n=3) cells where plakoglobin has been suppressed. (C-D) Quantification 
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of junctional plakoglobin signal before and after shear in (B) untreated (n=3) or (C) SB216763 
treated (n=3) cells where plakophilin has been suppressed. 
 
Figure 4.5 - SB216763 treatment, but not GSK3 suppression, rescues wild-type phenotype: 
Quantification of junctional plakoglobin signal before and after shear in non-targeting siRNA 
treated (n=3) or GSK3 siRNA treated (n=3) cells transfected with wild-type or mutant 
plakophilin. Suppression of GSK3 siRNA did not mimic the effects of SB216763. Suppression 
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1.1 – Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
1.1.1 – Clinical Presentation, Prevalence and Pathogenesis 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease affecting roughly 
1 in 5000 people worldwide, and is exhibited morphologically as fibro-adipocytic replacement of 
the ventricular myocardium.1, 2 Specifically, ARVC usually originates in the right ventricular 
epicardium between the conus arteriosus and ventricular apex, referred to as the ‘triangle of 
dysplasia,’ yet reasons for this localization remain unknown.1, 3, 4 The gradual replacement of 
myocardium with fibrous, fatty tissue can cause hypokinesis of the affected tissue, causing early 
stage palpitations, ventricular tachycardia or syncope, prior to sudden cardiac death (particularly 
following exertion). Without treatment, life expectancy can be highly variable from patient to 
patient, depending on phenotypic expression, although normal life expectancy can be restored 
with early detection and the right treatment. Unfortunately, the clinical diagnosis of ARVC can 
be difficult, even with recently proposed amendments to the 1994 International ARVC Task 
Force Criteria. Patients can be diagnosed with the condition by satisfying 2 (out of 10) major 
criteria, or 1 major and 2 (out of 15) minor criteria.5  One commonly satisfied criteria is the 
identification of a pathogenic mutation associated with ARVC. 
Typically involving autosomal dominant transmission, multiple studies have identified 
ARVC-causing mutations in genes encoding proteins that localize at the desmosome, a highly 
ordered junctional protein complex that enhances cell-cell adhesion, stabilizes gap junctions, and 




encoding the cardiac ryanodine receptor (RYR2) and transmembrane protein 43 (TMEM43), 
although the frequency of these mutations in patients diagnosed with ARVC is rare.16, 17 Because 
desmosomes contribute to tissue integrity by linking the intermediate filament networks of 
adjacent cells, the expression of mutant ARVC-causing desmosomal proteins have led many 
investigators to hypothesize that defective cell-cell adhesion plays a critical pathogenic role. 
Interestingly, there is no direct evidence of weakened cell-cell adhesion in the hearts of patients 
with ARVC.  
One hypothesis for ARVC etiology suggests desmosomal disruption can cause nuclear 
translocation of plakoglobin, and can recapitulate the ARVC phenotype by suppressing the 
canonical Wnt/beta-catenin signaling pathway, and resulting in a transcriptional switch to 
adipogenesis.18, 19 Another hypothesis suggests that the gap-junctional remodeling resulting from 
cell-cell adhesion defects may affect signal conduction across the myocardium, producing the 
hallmark arrhythmogenic phenotype associated with ARVC.20  
While inconsistent phenotypic presentation and variable genetic penetrance can make the 
condition difficult to diagnose, certain features of ARVC present consistently. For example, 
strenuous exercise increases age-related penetrance, risk of arrhythmia and sudden cardiac death, 
particularly in athletes.21-23 Interestingly, little investigation has been done into the effects of 
mechanical stresses on disease progression. 
 
1.1.2 – In Vivo and In Vitro Models of ARVC  
Despite the fact that ARVC Task Force criteria have yet to be developed for animal 
models, it is widely accepted that rodent, feline, canine, bovine and primate species can all 
develop an ARVC phenotype similar to the human condition (canine and bovine species can 
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present with an ARVC-like phenotype independent of genetically manipulated animal 
models).24-27 Murine models have been primarily used to study ARVC progression, as they 
provide the most convenient way to study the condition in vivo. While these models recapitulate 
the human phenotype well in terms of arrhythmogenicity and fibrosis, none exhibit the fatty 
infiltration observed in humans.28 Larger animal models (feline, canine, bovine and primate) are 
difficult to house and maintain, but tend to exhibit the fatty tissue deposition observed in 
humans. Furthermore, the similarity in cardiac structure between these larger animals and 
humans offers an opportunity to study the mechanical properties of the heart, using 
electromechanical wave or diffusion tensor imaging techniques.      
Several mouse models have been developed to study the molecular mechanisms 
underlying ARVC pathogenesis, and they focus on 4 major desmosomal proteins – plakoglobin, 
plakophilin-2, desmoplakin and desmoglein-2 (Table 1).6, 29-34 Earlier models attempted to 
recapitulate the ARVC phenotype by deleting whole or partial genes. While the models 
expressing homozygous deletions generally resulted in embryonic lethality, analysis of embryos 
at different developmental stages provided valuable insight in to the role of desmosomal gene 
regulation on cardiac structure and function during development. The first investigations into the 
effects of targeted deletion of the plakoglobin gene were conducted by Bierkamp, et al. and Ruiz, 
et al.29, 30 Independently, both groups observed that homozygous deletion of the plakoglobin 
gene resulted in embryonic lethality as early as 10 days into gestation. Interestingly, 
heterozygous models, expressing one mutated allele and one wild-type allele, exhibited much 
higher viability and more accurately recapitulated the ARVC phenotype (arrhythmia, enlarged 
right ventricles, etc). This effect was also observed in mice expressing desmoplakin deletions.33  
Furthermore, Kirchhof, et al. was able to link endurance training to an aggravation of the ARVC 
4 
 
phenotype. While exercise can induce changes independent of the increased mechanical stress, 
this data supports the hypothesis that susceptibility to mechanical forces may contribute to 
ARVC pathogenesis in heterozygous plakoglobin deficient mice.31 
Although more ARVC-causing mutations have been identified within the plakophilin-2 
gene than any other gene encoding a desmosomal protein, few models have been developed to 
study the role of mutant plakophilin in disease progression. One such model was developed by 
Grossman, et al. Similar to previous plakoglobin studies, their results showed that mice with 
homozygous deletions of the plakophilin-2 gene were embryonically lethal, while heterozygous 
mice carrying one functional plakophilin-2 allele were completely viable, with no observable 
cardiac phenotype. These data suggest that the cause of ARVC may not be due to a complete loss 
of desmosomal protein function, but rather from the expression of a mutant protein, with a 
possible gene dosage effect. 
More recently, groups have begun studying the effects of transgene expression, as 
opposed to whole or partial gene deletion, in order to more accurately recapitulate the ARVC 
phenotype.6, 34, 35 For example, Yang et al. created several transgenic mice with a cardiac 
overexpression of either C-terminal (Q90R and V30M) or N-terminal (R2834H) mutant 
desmoplakin. Interestingly, mice expressing C-terminal desmoplakin mutations exhibited 
embryonic lethality similar to mice developed by Gallicano, et al, which expressed a cardiac 
specific C-terminal desmoplakin deletion (Δ281-473).33, 34 In contrast, mice that expressed the 
R2834H mutation were successfully generated, and exhibited increased apoptosis / fibrosis, and 
reduced ventricular function relative to wild-type litter mates. These data suggest that C-terminal 
mutations may have an adverse effect on embryonic development, and that gene deletions may 
not accurately recapitulate a disease phenotype caused by the expression of a mutant protein. 
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In vivo studies are often presumed to be the ‘gold standard’ for studying disease 
pathogenesis, but in vitro models have also been successfully exploited to study ARVC. Despite 
the progress made in understanding ARVC etiology through in vivo studies, mouse models fail to 
recapitulate the fatty infiltrations observed in humans. The mechanism by which fatty tissue 
infiltrated the myocardium remained a mystery until Garcia-Gras, et al. used the HL-1 cell line 
(immortalized atrial myocytes) to show that siRNA knockdown of desmoplakin resulted in a 
transcriptional switch to adipogenesis, as determined by semi-quantitative RT-PCR.18 In vitro 
studies have also been able to shed light on how mutant desmosomal protein expression can alter 
the intracellular distribution of connexin-43. Because desmosomes play a supporting role in 
structural integrity of gap junctions, desmosmal defects could cause destabilization of gap 
junctions, and contribute to arrhythmogenesis by altering the normal electrical coupling between 
cardiac myocytes. Other studies have attempted to use patient-specific induced pluripotent stem 
cells to better characterize the disease in humans. For example, in 2013 Kim, et al. demonstrated 
that induced pluripotent stem cells expressing mutant plakophilin 2 exhibited some 
characteristics found in mouse models, such as nuclear translocation of plakoglobin.36 They were 
also the first to report that the induction of an adult-like metabolism may underlie the 
pathogenesis of ARVC, which supports the clinical finding that ARVC symptoms usually 
present after puberty.37 These studies show the development of in vitro models of ARVC may 
provide insight into the molecular mechanisms underlying patient-specific disease pathogenesis.  
   
1.1.3 – Treatment Options for ARVC Patients 
 ARVC is a degenerative condition for which the underlying defective molecular 
mechanisms are not well defined, and no treatments exist to completely cure ARVC. Recent 
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studies have provided a wealth of information regarding the link between exercise and disease 
progression, supporting the most widely implemented disease management strategy of limiting 
physical exercise.21-23 However, treatment options are available to mitigate the symptoms 
associated with ARVC, which include anti-arrhythmic medications, implantable cardioverter 
defibrillator (ICD) therapy, and catheter ablation.38 If diagnosed early enough (i.e. – early 
adulthood), treatment with anti-arrhythmic medication and / or ICD therapy can alter the course 
of ARVC progression.  
The current way clinicians interpret the typically non-specific clinical features of the 
disease, and arrive at a diagnosis, is to refer to ARVC Task Force criteria.5 Unfortunately, these 
criteria tend to focus on features, such as overt changes in cardiac structure, fibrofatty infiltration 
of the myocardium, and conduction alterations, that tend to occur in patients that have progressed 
past the concealed stage. Early detection and treatment can provide a normal life-expectancy for 
patients, with less than 10% of patients progressing to overt right ventricular failure, and the 
need for heart transplant.39-41 While each treatment option aims to fix the characteristic 
arrhythmia associated with the condition, disease management strategies are often 
individualized, with diagnoses depending on continued monitoring and symptom improvement. 
The clinical challenges that remain are identifying the condition at an early stage, and improving 
risk stratification by determining which combination of disease management strategies work best 
for a particular patient.42 Addressing either of these challenges requires further investigation into 
the defective molecular mechanisms underlying the condition.   
   
1.2 – Mechanotransduction in Cardiac Myocytes 
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External stimuli play an important role in cardiac tissue remodeling through the 
regulation of key intercellular adhesion proteins such as N-cadherin, plakoglobin, and connexin-
43.43-47 While previous studies of mechanotransduction in cardiac myocytes have characterized 
responses of monolayers of cultured myocytes to stretch,48 responses to shear stress may also be 
particularly pertinent. For example, recent studies by Boycott, et al. demonstrated that shear 
stress was able to induce voltage-gated potassium channel remodeling in atrial myocytes.49 It 
remains to be seen if shear stress plays a role in cardiac myocytes expressing ARVC-causing 
mutant proteins. 
Interestingly, patients expressing the 2057del2 ARVC-causing plakoglobin mutation 
present with keratoderma in regions of the skin (i.e. – palms and soles) that specifically 
experience shear stress. Similarly, the effects of shear stress may be amplified in structurally 
weak regions of the heart, and may explain why ARVC preferentially affects the triangle of 
dysplasia, which represents thinner regions of the right ventricle.50 
In vivo, cardiac myocytes are organized into a laminar, sheet-like architecture with loose 
collagenous coupling between sheets.  Relative movement of these laminar sheets during the 
cardiac cycle may cause direct shearing between adjacent sheets or shear from interstitial fluid 
motion.51, 52 Canine studies, for example, have identified myocardial shear as a significant factor 
in wall thickening.53, 54 Additionally, short-term fluid shear stresses of 90 to 600 mdyn/ cm2 
regulate expression of a wide variety of cardiac markers in rat cardiac myocytes, including the 
contractile proteins α-sarcomeric actin and troponin-T, the gap junction protein connexin43 
(Cx43), and the cell-cell adhesion protein N-cadherin without affecting phosphorylation of p38, 
an established marker of cell apoptosis.55, 56 For cardiomyopathies affecting anchoring cell-cell 
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junctions, such as ARVC, the regulation of these proteins can alter tissue cohesion, intercellular 
signaling, and even regulate cell viability. 
 
1.3 – Motivation, Specific Aims and Organization 
1.3.1 – Motivation 
There is increasing evidence that suggests mechanical stress plays a critical role in 
promoting the cardiac phenotype, which may be altered in ARVC. To that end, the goal of this 
work is to determine how ARVC-causing mutant desmosomal proteins alter the mechanical and 
signaling properties of cardiac myocytes, and their ability to respond to mechanical stimuli. 
Previous studies of mechanotransduction in cardiac myocytes have characterized responses of 
monolayers of wild-type myocytes, but how individual mutant desmosomal proteins might affect 
the cell’s ability to respond to mechanical stimuli has yet to be determined.  
In order to better understand the role of ARVC-causing mutant proteins on the 
mechanical and structural properties of the heart and its role in ARVC pathogenesis, we first start 
by studying the native right ventricular myocardium. Next, we aim to determine the role of 
ARVC-causing mutant plakoglobin on the mechanical properties of cardiac myocytes and their 
response to mechanical stress. Finally, in order to improve risk stratification for ARVC patients, 
there exists a critical need to first determine if mutations in different desmosomal proteins result 
in common mechanical and signaling defects. Accordingly, we aim to assess whether the 
observed changes in cardiac myocytes expressing ARVC-causing mutant plakoglobin are similar 
to those observed in myocytes expressing a more frequently mutated protein (i.e. – plakophilin). 
  
1.3.2 – Specific Aims 
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We propose to address the following specific aims: 
 
Aim 1. Characterize the mechanical strains and structural properties of the native right 
ventricular myocardium 
Hypothesis: The right ventricular apex experiences altered fiber orientation and heterogeneous 
strain distributions 
 
Aim 2. Assess changes in the mechanical and signaling properties of cardiac myocytes 
expressing ARVC-causing mutant plakoglobin 
Hypothesis: The expression of ARVC-causing mutant plakoglobin alters the mechanical 
properties of cardiac myocytes (i.e. cell-cell adhesion and cell stiffness), and their ability to 
respond to mechanical stimuli (i.e. – junctional protein remodeling). 
 
Aim 3. Determine if ARVC-causing mutations in different genes encoding desmosomal 
proteins result in similar alterations in mechanical and signaling properties  
Hypothesis: Cardiac myocytes expressing ARVC-causing mutant plakophilin exhibit altered 
mechanical and signaling properties similar to those observed in cells expressing mutant 
plakoglobin.   
 
1.3.3 – Organization 
 This work is organized into three major sections, focused on elucidating how mechanical 
forces affect the structural and mechanical properties of cardiac myocytes expressing ARVC-
causing mutations. To this end, we first need to understand the structural and mechanical 
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properties of the native right ventricular myocardium. In Chapter 2, we use histology and 
immunofluorescence to characterize the structural properties of left ventricular, septal, and right 
ventricular healthy heart walls. Furthermore, we employ elastography techniques to investigate 
the mechanical forces throughout the heart. Generally, we focus our attention on the right 
ventricular apex, owing to the fact that this region is a point of origin for the fibrofatty tissue 
infiltration associated with ARVC. 
 In Chapters 3 and 4, we transition to in vitro models of ARVC. Using adenoviral 
infection, we express either mutant ARVC-causing plakoglobin (Chapter 3) or plakophilin 
(Chapter 4) in neonatal rat ventricular myocytes, and use an array of techniques to investigate the 
mechanical and signaling properties of these cell models. Plakoglobin was chosen for 
investigation for its proposed central role in ARVC pathogenesis. We investigate mutant 
plakophilin-2 because of its prevalence among the ARVC patient population. We develop and 
use dispase and aggregate assays to measure cell-cell adhesion properties, atomic force 
microscopy to measure cell stiffness, and quantitative confocal microscopy to measure changes 
in junctional protein localization. We repeated key assays in the presence of shear stress, to 
determine how ARVC-causing mutant proteins affect myocyte behavior under physiologically 
relevant mechanical stress. Finally, in order to learn more about common underlying defects 
across different ARVC-causing mutations, we compare the response of native plakoglobin and 
plakophilin in myocytes expressing ARVC-causing mutant plakophilin or plakoglobin, 
respectively. 
 In Chapter 5, we conclude by summarizing the results of this thesis work. Furthermore, 
we discuss the overall impact this work has had in the field, and the potential for future studies 
based on these results.  
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1.4 – Tables 
 
Protein Gene Mutation Mutation Type Reference 
Plakoglobin JUP Exons 3-5 Deletion (Homozygous) Bierkamp (1996) 
  Exons 3-5 Deletion (Heterozygous) Bierkamp (1996) 
  
Exon 3-4 Deletion (Homozygous) Ruiz (1996) 
  Exon 3-4 Deletion (Heterozygous) Ruiz (1996) 
Plakophilin PKP2 Exon 1 Deletion (Homozygous) Grossman (2004) 
  
Exon 1 Deletion (Heterozygous) Grossman (2004) 
Desmoplakin Dsp Δ281-473 Deletion Gallicano (1998) 
  
Wild-type Transgene Yang (2006) 
  
R2834H Transgene Yang (2006) 
  
Q90R Transgene Yang (2006) 
  
V30M Transgene Yang (2006) 
Desmoglein Dsg2 Wild-type Transgene Pilichou (2006) 
  
N271S Transgene Pilichou (2006) 
    * Mutations resulting in embryonic lethality 
  
 
Table 1.1: Summary of ARVC mouse models used to study disease pathogenesis - From left to 
right, the columns identify the protein being affected, the gene being mutated, the exact mutation 
being investigated, the type of mutation, and the associated reference. These models focus on 4 
out of 5 major desmosomal proteins thought to cause ARVC when mutated; no mouse models 


























Figure 1.1: Hierarchy of desmosomal architecture – (Top) Neonatal rat ventricular myocytes 
immunostained for the desmosomal protein plakoglobin. (Middle) Scanning electron micrograph 
of a desmosomal junction, showing why desmosomes are described as ‘cellular spot welds’. 
(Bottom) A graphic showing how the desmosomal proteins plakoglobin (green), plakophilin 
(blue oval), desmoplakin (blue dumbbell), desmoglein (red) and desmocollin (orange) may 
organize at cell-cell junctions in order to link the intermediate filament networks of adjacent 




Cell – Cell 
Junctions 
Scanning Electron Micrograph Adapted From: Fawcett DW, The Cell: An Atlas of Fine Structure, p. 371 
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 Characterizing the Structural and Mechanical  
    Properties of the Native Heart 
 
  
2.1 – Introduction 
 The right ventricle of the heart is a secondary chamber whose structure is 
morphologically distinct from the left ventricle. In particular, the right ventricle ‘wraps’ around 
part of the left ventricle, so that the right ventricular chamber is more crescent-shaped than 
circular. Because the right ventricle is similar to an ‘added’ wall of the heart, cardiac structure 
can exhibit discontinuitie1s and experience altered mechanical stresses where the right 
ventricular lateral wall meets the septum, and in particular at the right ventricular apex (RVA), 
which must merge with the septum in multiple directions. Because myocytes typically form 
adhesion complexes end-to-end, discontinuous or juxtaposed myofibers could result in 
diminished junctional protein expression (i.e. – desmosomes, gap junctions, etc.), affecting 
electrical conduction across the myocardium. In fact, the RVA is a key site for development of 
arrhythmias and a potential pacing target, although recent large, randomized clinical trials have 
begun to correlate pacing at the RVA with a worse clinical outcome in patients with various 
arrhythmia diseases (i.e. - arrhythmogenic cardiomyopathy, Brugada Syndrome, etc.).2-5 It has 
been proposed that the detrimental effects of pacing at the right ventricular apex can be attributed 
to an abnormal electrical activation pattern in the ventricles (i.e – conduction of the electrical 
wavefront through the myocardium instead of the His-Purkinje fiber system).6 A careful 
characterization of the structure of the RVA is essential for understanding its role in cardiac 
physiology.  
Further, the tendency for arrhythmia development may depend in part on the physical 




structural and mechanical properties of the RVA, expanding on earlier studies that primarily 
focus on general fiber orientation within the ventricle itself, may yield new information on the 
influence of RVA anatomy on the progression of some diseases.7, 8 For example, 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) preferentially affects the right 
ventricular epicardium between the conus arteriosus and ventricular apex, referred to as the 
‘triangle of dysplasia,’ yet reasons for this localization remain unknown.9-11 One study notes the 
triangle of dysplasia likely represents thinner regions of the right ventricle, but without definitive 
data.12 While many conditions have underlying causes (genetic, molecular, etc.) exacerbating 
their symptoms, the hearts are typically structurally normal when the patient is young. Thus, it is 
worthwhile examining healthy hearts to determine whether there is any reason underlying the 
RVA’s tendency to be involved in pacing and structural alterations. 
Two methods for examining the structural properties of myocardial tissue are histology 
and diffusion tensor imaging, both having their own advantages and disadvantages. Histological 
analysis involves embedding tissue in paraffin wax, and taking planar sections of tissue, which 
can then be analyzed further (i.e. – immunofluorescence staining). Of the two, histology is the 
only technique that provides direct evidence of cardiac fiber orientation, as it requires sectioning 
the actual tissue, but limits the data acquisition to two dimensions, and can result in minor 
aberrations at the tissue periphery. Furthermore, histology requires fully infiltrating a tissue 
sample with embedding media (such as paraffin wax), limiting the size of the tissue construct 
that can be studied without tissue reconstruction. Diffusion tensor imaging, on the other hand, is 
a technique that uses magnetic resonance imaging to track the diffusion of water through tissue. 
In cardiac tissue, water generally moves through the myocardial fibers (the path of least 
resistance), which allows for the 3-dimensional mapping of cardiac fibers throughout the heart. 
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While this technique is less invasive than histology, the data cannot be used to draw conclusions 
at the molecular level (which requires immunostaining of histological sections). In order to study 
both the cardiac fiber orientation as well as the junctional localization of key cell-cell adhesion 
proteins (i.e. – plakoglobin and N-cadherin), we chose to use histological analysis. To measure 
the mechanical properties of the heart, we collaborated with the Ultrasound Elasticity Imaging 
Laboratory at Columbia University to use elastography – a non-invasive, ultrasound-based 
imaging technique that can be used to determine local tissue strain by cross-correlating RF 
segments throughout the cardiac cycle to calculate the arrival time-shift of an echo in a deformed 
region of tissue.13, 14 While other motion-estimation techniques are also available for the study of 
myocardial strains (i.e. – Doppler myocardial imaging or Strain rate imaging), they are phase-
shift based methods that require autocorrelation, which can limit the signal bandwidth that can be 
used (i.e. – resulting in low axial resolution).15-17 Elastography is a time-shift based technique 
(proven to overcome the limitation of low axial resolution faced by phase-shift based techniques) 
that has been validated in myocardial tissue, and can be used to calculate the incremental axial 
displacements and strains.15-18 
Because of a potential interplay between structure and mechanical stresses at the RVA, 
we propose a biomechanical hypothesis: regions of structural disarray, coupled with altered 
(elevated or heterogeneous) mechanical strains, may contribute to development of arrhythmias 
and altered tissue responses, and that these effects are exacerbated in certain disease processes. 
To test this hypothesis in the context of the RVA, we performed a systematic analysis of the 
structural features and mechanical strains in the heart, focusing on the RVA region. We 
examined healthy hearts from canines (suitable for elastography measurements and histological 
analysis) and rats (suitable for large-scale histological and immunofluorescence analysis) and 
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show that the RVA exhibits persistent elevation and significant gradients in mechanical strains, 
and diminished organization of a key junctional protein. These results support the 
‘biomechanical’ hypothesis, and explain why the RVA may be predisposed to initiation of 
pathological tissue development and represents a hot spot for conduction abnormalities, 
independently of specific disease processes.  
 
2.2 - Methods 
2.2.1 – Histology 
 Whole rat hearts were extracted via cardiectomy from sacrificed (1-day) post-partum 
adult rats and fixed for 24 hours in 4% paraformaldehyde. Septal, left and right ventricular (S, 
LV and RV, respectively) sections were dissected along the long-axis planes of the heart. Right 
ventricular sections included myocardium inferior to the apex of the right ventricle, but not 
extending to the apex of the heart, while left ventricular samples consisted of tissue extending to 
the apex of the left ventricle, and myocardium from the right ventricular uptract. Septal sections 
did not include epicardial tissue. Samples were dehydrated with ethanol, cleared with xylene, and 
embedded in paraffin, taking care to preserve orientation and landmarks to ensure the right 
ventricular apex could be located. Epicardial sections were sectioned into 5 µm thick samples 
and mounted on glass slides.  Left and right ventricular sections were taken along the epicardial 
wall, while septal sections were taken from myocardium lining the right ventricle. Sections were 
subsequently stained using the Chromaview Masson Trichrome Kit (Sigma, St. Louis, MO) 
according to the manufacturer’s protocol, and mounted with Permount Mounting Medium 
(Fisher Scientific, Waltham, MA). Canine samples were obtained from formalin fixed whole 
hearts. Epicardial LV and RVA samples were dissected from the LV wall (toward the apex) and 
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where the RV lateral wall meets the septum, respectively. Samples were processed identically to 
rat heart samples. All animal work was performed in accordance with the Institute of 
Comparative Medicine at Columbia University. 
 
2.2.2 – Structural Analysis 
 Rat and canine heart histological sections were imaged under bright field microscopy 
using a 4x, NA 0.13 objective on an Olympus IX-81 microscope (Center Valley, PA). Individual 
images were assembled using the FIJI plug-in for ImageJ to produce a single high-resolution 
image of the entire ventricular or septal wall, orienting the apex-base axis vertically with the 
apex toward the bottom. Line plots were hand-drawn by tracing local fiber orientation, as 
assessed visually. Lines were omitted at fiber bifurcations and regions where fiber orientation 
was visually ambiguous. Fiber direction was quantified in septal, left and right ventricular 
samples with color mapping using Matlab (Natick, MA); a 20 x 20 grid was used to discretize 
each image into cells where the fiber orientation was determined using a line segment parallel to 
the local fiber direction (Appendix 2.6). The cosine of each angle was determined in the range of 
0 to 180 degrees, and scaled to a gray-scale map, where horizontal and vertical fibers correspond 
to black and white, respectively. This map provides a visualization of changes in fiber orientation 
within a single wall; the greater the changes in fiber orientation, the larger the amount of 
variance in grayscale. Analysis of fiber direction was performed by determining the percentage 
of cells within each 20 x 20 grid (Rat n=4; Canine n=2 for each wall) where the cosine of the 
angle was greater than 0.3, corresponding to cells with vertically oriented fibers. 
 
2.2.3 – Immunofluorescence 
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 Rat myocardial samples were immunostained using established protocol.19 Paraffin-
embedded samples were re-hydrated and boiled in citrate buffer (pH 6.0) for 11 minutes. After 
cooling to room temperature, tissue sections were concurrently blocked and permeabilized for 45 
minutes (3% normal goat serum, 1% w/v BSA, and 0.15% Triton X-100 in PBS). Samples were 
then incubated with either mouse-monoclonal anti-plakoglobin (Sigma; 1:400 in blocking buffer) 
or anti-pan cadherin (Sigma; 1:400) antibody overnight at 4 oC, followed by a two-hour 
incubation with the secondary antibody (diluted 1:1000) on day two at 25 oC. Fluorescently 
labeled samples were then mounted with Permount Mounting Medium and imaged using an 
Olympus IX-81 fluorescence microscope and analyzed using Metamorph and ImageJ. 
Quantitative microscopy was used to determine JUP and PC signal intensity in regions of fiber 
disarray relative to regions with uniform fiber orientation. ImageJ was used to threshold 
fluorescence images to isolate junctional JUP or PC signal, and determine the fraction of pixels 
above threshold over pixels in the image space. 
 
2.2.4 – Elastography 
Elastography data was acquired following established protocol.20 Two mongrel dogs 
were anesthetized with injection of thiopental and fitted with standard limb leads for 
electrocardiogram monitoring. Morphine (0.15 mg/kg, epidural) was administered before 
surgery, and lidocaine (50 µg/kg/hr, intravenous) was used throughout the procedure. A 0.9% 
saline solution was supplied intravenously (5 mL/kg/hr) to maintain blood volume. 
Echocardiography was performed  using an Ultrasonix RP system with a 3.3 MHz phased array 
to acquire RF frames between 390 and 480 frames/sec via an automated composite technique.21 
Radial incremental (strain in one frame using the previous frame as reference) and cumulative 
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(change in strain relative to end-diastole) strains in the Eulerian description (motion relative to 
fixed spatial coordinates) were estimated by applying a least-squares estimator 22 on incremental 
and cumulative displacements, respectively. For example, if a thin wire were stretched with 
images taken at 1 Hz, the incremental strain would represent the change in length of the wire 
between two frames divided by the wires in the first of the two frames. The cumulative strain 
would represent the change in length of the wire relative to the original length of the wire, before 
being stretched. Incremental and cumulative strains23, 24 were calculated by taking a spatial 
average of strains throughout each wall at successive time points, using the roipoly function in 
Matlab (Natick, MA) to specify the polygonal region of interest.  Both whole-wall (WALL; 
Figure 2.6A, outlined in black) and smaller mid-wall regions of interest (MID-WALL; Figure 
2.6B, black squares) were used for strain quantification in order to provide large-scale data and 
variance in radial strain within the region of interest (modified from previous work 24), 
respectively. Mid-wall incremental strains were determined using an ROI toward the middle of 
each wall during the ECG when the peak incremental strain occurred (Figures 2.7C & 2.8C). 
Normality of the strains within the mid-wall region of interest was confirmed using the 
Kolmogorov-Smirnov test (p ≤ 0.05).  End-systolic mid-wall cumulative strain was also 
calculated using a region of interest toward the middle of each wall (Figures 2.7D & 2.8D). 
Standard errors for regional incremental and cumulative strains were calculated using strain 
values within each region of interest. Statistical significance was determined using analysis of 
variance (ANOVA) and Tukey’s test. All animal work was approved by the Institutional Animal 
Care and Use Committee of Columbia University. 
 
2.2.5 – Statistical Analysis 
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 Data were analyzed using the analysis of variance (ANOVA) test. Data showing 
significance (p ≤ 0.05) were further analyzed using either a Student’s T-test, Tukey or 
Bonferroni post-hoc tests. 
 
2.3 – Results 
 
2.3.1 – Cardiac Fibers at the Right Ventricular Apex (RVA) Exhibit Disarray 
To examine the structure of the ventricular walls and septum, histological techniques 
were used to enhance visualization of fiber orientation in samples obtained from rats and 
canines. Rat hearts were used due to their low epicardial fat and to facilitate the analysis of entire 
ventricular walls. Due to the thinness of rat heart walls, histological specimens are representative 
of both epicardium and endocardium.  
While disarray is used without formal definition in many cardiac structural studies, in this 
article disarray refers to abrupt changes in myocyte orientation signifying loss of straight end-to-
end coupling. In contrast with the LV and septal regions, myocyte disarray in the RV was a 
notable recurring theme in the samples, with cell-cell apposition typically occurring at or near 
the RVA region (Figures 2.1A-C and 2.2A-B, left column). There is significant variance in the 
degree and extent of this disarray, as well as its location, consistent with the highly variable 
penetrance of ARVC and arrhythmia development in clinical cases. 
To quantify this disarray, histological sections were color-mapped with shades of grey 
corresponding to the local fiber direction. In the RV, cell-cell juxtaposition ranged from 0 to 90 
degrees, whereas a more continuous change in fiber orientation was observed in the LV and 
septal regions as evidenced by the proximal localization of white and black cells in the gray-
scale mapped images of the right ventricle (Figures 2.1A-C and 2.2A-B, right column). In the rat 
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RV, 5.7 percent of cells contained vertically oriented fibers, while left ventricles and septums 
had 1.1 and 0.7 percent, respectively (Figure 2.1D; p ≤ 0.05 for LV vs RV, p ≤ 0.01 for SEP vs 
RV). In the canine RV, 37.75 percent of cells contained vertically oriented fibers, while left 
ventricles had 0.375 percent, respectively (Figure 2.2C; p ≤ 0.05 for LV vs RV). The right 
ventricular walls exhibit greater black/white distributions that are either focally located or 
randomly scattered, suggesting a degree of disarray in the right ventricular walls. In contrast, the 
left ventricular and septal walls exhibit more uniformity in their gray-box distribution. 
  
2.3.2 – Cell-Cell Junctional Protein Localization is Altered Near the RVA 
 In addition to overt structural disarray in the RVA region, immunohistochemical staining 
was performed in rat heart sections to assess the localization of both cadherin and plakoglobin at 
cell junctions.  Cadherins are adhesion molecules that hold together adjacent myocytes at their 
intercalated discs. Plakoglobin is a desmosomal protein that links desmin across adjacent 
myocytes. Plakoglobin is additionally implicated in ARVC, and its expression is altered even in 
cases where the disease-causing mutation is not in plakoglobin itself.25 Thus there is reason to 
believe that plakoglobin may help stabilize conduction and/or mechanical support pathways. 
Far from the RVA, cadherin staining was strong and similar in the left ventricular (Figure 2.3A), 
right ventricular (Figure 2.3B) and septal (Figure 2.3C) walls, mostly localizing at the end-to-end 
junctions between adjacent cardiomyocytes. Cadherin signals near the RVA exhibited 
diminished intensity levels, relative to the rest of the wall, with fiber apposition evident in the 
RVA region (Figure 2.3D & 2.3F; p=0.07). Plakoglobin also exhibits a similar drop-off in 
intensity near the RVA (p ≤ 0.05), suggesting diminished desmosomal expression in addition to 
fiber disarray (Figure 2.3E-F). Intercalated disk orientation near the RVA exhibits lower degrees 
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of end-to-end localization and regularity. These results are consistent across the hearts examined. 
Since desmosomes play a supporting role in gap-junctional architecture, altered 
electromechanical coupling in this region may account for previously observed idiopathic 
ventricular arrhythmias.26 
 
2.3.3 – Elastography Reveals Persistent, Elevated Strain in the Right Ventricle 
 Elastography measurements of incremental (change from frame to frame) and cumulative 
(change relative to end-diastole) mechanical strains were acquired along the length of the 
ventricular walls and septum of a canine heart (Figures 2.4 and 2.5 showing incremental and 
cumulative strain superimposed on the echocardiography data, respectively). Canine hearts were 
used due to similarity of their physiology to the human heart, thus being well-suited for 
elastography measurements.  
The RVA exhibits strong sharp changes in the distribution of both incremental strain and 
cumulative strain (Figures 2.6A-B). In particular, there are sharp transition regions of strain near 
the RVA, and especially in Heart 1, peak strains occur near the RVA region. These data suggest 
that the RVA may be prone to unusual mechanical load distributions due to local load 
heterogeneity, and in some cases, experience elevated loading. 
Quantitative analysis of strain data reveals elevated and sustained incremental and 
cumulative strains within the RV wall, as compared to the LV wall, during systole (Figures 
2.7A-B & 2.8A-B).  Mid-wall incremental systolic strains are 0.0056 ± 5.5x10-4 and 0.0045 ± 
2.2x10-4 in the right ventricle and 0.0024 ± 5.3x10-5 and 0.0017 ± 4.0x10-5 in the left ventricle, 
respectively, corresponding to 133 and 165 percent increases in incremental strain (Figures 2.7C 
& 2.8C; p ≤ 0.01). Mid-wall incremental systolic strains are 0.0043 ± 1.6x10-5 and 0.0017 ± 
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2.5x10-4 in the right ventricular apex. Since incremental strains represent the change over a short 
time-span, higher incremental strains suggest a more abrupt load on the myocytes. 
Whole-wall cumulative strains during systole are persistently elevated for the right 
ventricle compared to the left ventricle during systole, although not for diastole (Figures 2.7B & 
2.8B).  Further, data demonstrate that changes in cumulative systolic strains (end systolic strain 
minus beginning systolic strain) in the RV wall are greater than that of the LV wall. Mid-wall 
cumulative end-systolic strains are 0.15 ± 0.026 and 0.11 ± 0.013 in the right ventricle and 0.094 
± 0.0058 and 0.077 ± 0.0014 in the left ventricle, representing 1.6 and 1.4-fold increases in 
cumulative strain (Figures 2.7D & 2.8D; p ≤ 0.01). Mid-wall cumulative end-systolic strains are 
0.061 ± 0.010 and 0.059 ± 0.007 in the right ventricular apex. Similar elevations are found for 
diastolic strains. The cumulative strain values obtained for the LV are consistent with those 
found in literature, from both experimental observations and computational studies, indicating a 
peak strain of approximately 10% near the basal region of the heart from diastole to systole.27, 28  
These data show that the RV wall bears higher strains for longer periods of time, has elevated 
changes in strain over short times, and near the RVA, experiences heterogeneity in strain 
distribution in a small volume. Interestingly, both mid-wall and whole-wall septal cumulative 
strains are comparable to, or greater than, RV cumulative strains. Additionally, the RVA itself 
does not exhibit particularly elevated strain magnitudes (incremental or cumulative), compared 
to the rest of the heart.  Thus, elevated, persistent and heterogeneous mechanical strains by 
themselves are likely not sufficient to explain the RVA as a site for conduction abnormalities. 
 




The work in this chapter was meant to characterize the mechanical strains and structural 
properties of the right ventricular myocardium. Of particular interest in our investigation was the 
right ventricular apex, a region notorious for disease development. We  show, via tissue-level 
examination of cardiac structure and mechanical strain that (1) the region near the right 
ventricular apex exhibits structural disarray, (2) the right ventricular apical region exhibits less 
organized intercalated disk orientation and diminished desmosomal expression, and (3) there are 
persistent, elevated strains and changes in strain over short distances in the right ventricle, during 
systole.  Disarray near the RVA region likely contributes to structural weakness since the lateral 
adhesion strength of the fibers is likely lower than the end-to-end strength. Further, during 
systole, when the intramuscle strength needs to be high to maintain tissue cohesion, the right 
ventricle, and sometimes the RVA, experiences elevated strains, compared to the left ventricle. 
Thus, heterogeneous fiber orientation, coupled with increased incremental strains, effectively 
create a “weak spot” in the heart. The diminishment or disorganization of plakoglobin near this 
region may further weaken the heart or lead to conduction alterations.  
Our results thus support the “biomechanical” hypothesis, and provide supporting 
evidence for the need to study how ARVC-causing mutations may affect cell-cell adhesion 
strength and junctional protein localization in the presence of physiologically relevant 
mechanical stimuli (Chapter 3). While our study does not address a specific disease process, 
some motivation for examination of the RVA region came from ARVC. One primary hypothesis 
for the etiology of ARVC is that defects in cell-cell adhesion lead to destabilization of cell-cell 
interactions and disruption of junctional associations. Observations that desmosomal mutations 
causing ARVC do not generally lead to defects in other desmosome-expressing tissues (with 
skin/hair involvement being a notable exception) support this hypothesis, since the heart tissue is 
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under persistent, cyclic, elevated mechanical stresses. Our study is consistent with this 
hypothesis and explains further why the RVA has mixed results as a target for cardiac pacing. 
To test our biomechanical hypothesis we did not examine disease model hearts, opting 
instead to examine cardiac structures and strains to determine how they may contribute to disease 
development. For example, cardiac structure appears unaltered in the early stages of conditions 
such as ARVC,29 manifesting primarily after puberty. Thus, ARVC (and other conduction 
abnormalities) may not necessarily be the result of a priori alterations in cardiac tissue; they may 
simply initially manifest at hot spots such as the RVA.  The variability we report may also 
explain why ARVC does not always manifest primarily at the triangle of dysplasia (or indeed, 
necessarily the right ventricle). 
Examination of intact bovine hearts revealed a significant fatty deposit around the 
superior circumference of the heart, some mild fatty streaks following the left-anterior 
descending coronary artery, and notably, the right-ventricular apical region, but not the primary 
cardiac apex (Figure 2.9). As bovine (and canine) species can naturally develop phenotypes 
similar to the ARVC phenotype observed in humans, the presence of fatty streaks in the native 
bovine heart may indicate a predisposition for fibrous tissue infiltration near the right ventricular 
apex that may be exacerbated under disease conditions. Further, superficial examination of the 
heart structure shows that the bovine heart RVA region exhibits similar fiber disarray observed 
in rat hearts. Thus, the phenomenon we report is likely broadly applicable across mammalian 
hearts and may explain the presence of ARVC-like syndromes in cows and dogs, and provide 
support for use of different mammalian species in our analysis.  Further examination, using more 
sophisticated techniques (such as diffusion-tensor imaging), direct mechanical testing of the 
RVA tissue and molecular analysis of RVA mechanotransduction, are warranted. Examination of 
35 
 
the other locations of the triangle of dysplasia may be insightful, but were not done in this study 
because of reduced roles in cardiac conduction issues and difficulty of access for quantitative 
analysis. Heterogeneity in general fiber disarray and mechanical strains in the present study offer 
a potential explanation for the varying penetrance in ARVC development as well as variability in 
cardiac pacing using the RVA.3, 4 
We show that healthy right ventricles exhibit fiber disarray and diminished plakoglobin 
expression, specifically at the right ventricular apex, and experience elevated strains during 
systole relative to the left ventricle. Together, these results provide supporting evidence for why 
the RVA is a hot spot for development of arrhythmias. In particular, these results support the 
“biomechanical” hypothesis that regions exhibiting both weakened structure and elevated strains 
are likely to be a focal point for cardiac conduction abnormalities, and motivate our need to 
study the effects of ARVC-causing proteins on cell-cell adhesion and junctional protein 




























Figure 2.1: Fiber disarray occurs at the right ventricular apex in the mouse heart - Representative 
epicardial sections of (A) left-ventricular, (B) septal, and (C) right-ventricular regions of the rat 
heart with streamlines (line plots, middle column) to enhance visualization of myocyte fiber 
direction. Color mapping of fiber orientation in left-ventricular, septal, and right-ventricular 
sections (right column) shows a localization of vertical fibers (white) near the RVA region 
apposing fibers with a horizontal orientation (black), in contrast with the left-ventricular and 
septal sections. (A-C) Scale bar = 2mm; (D) Quantification of angle mapping in left-ventricular 
(LV), septal (SEP), and right-ventricular rat heart sections showing the percentage of cells where 












Figure 2.2: Fiber disarray occurs at the right ventricular apex in the canine heart - Representative 
epicardial sections of (A) left-ventricular, and (B) right-ventricular regions of the canine heart 
with streamlines (line plots, middle column) to enhance visualization of myocyte fiber direction. 
Color mapping of fiber orientation in left-ventricular, septal, and right-ventricular sections (right 
column) shows a localization of vertical fibers (white) near the RVA region apposing fibers with 
a horizontal orientation (black), in contrast with the left-ventricular section. (A-B) Scale bar = 
500 µm; (C) Quantification of angle mapping in left-ventricular (LV) and right-ventricular 





















Figure 2.3: Diminished plakoglobin expression occurs at the right ventricular apex in the mouse 
heart - (A) Left-ventricular, (B) right-ventricular, and (C) septal myocardial samples 
immunostained against pan-cadherin. The localization of expression is predominantly at the end-
to-end junctions of the myocytes. Scale bar = 100 µm. (D) Cadherin stained region of cardiac 
tissue including the RVA and some tissue peripheral to the RVA. (E) Plakoglobin stained region 
of cardiac tissue including the RVA and some tissue peripheral to the RVA. The upper-middle 
region, representing the RVA, exhibits weaker staining and less organization of intercalated 
disks. Scale bar = 250 µm. (F) Quantification of plakoglobin (JUP) and pan-cadherin (PC) signal 






Figure 2.4: Elevated incremental strains occur at the right ventricle during systole - Spatial 
distribution of incremental radial strains, superimposed on echocardiogram, across canine 
ventricular walls at different time points in one complete ECG cycle (denoted by red dots).  The 
left ventricular wall (LVW) is shown at the top of the image, followed by the septum (SEP) in 
the middle and the right ventricular wall (RVW) at the bottom. Incremental strains are 













Figure 2.5: Elevated cumulative strains occur at the right ventricle during systole - Spatial 
distribution of cumulative radial strains, superimposed on echocardiogram, across canine 
ventricular walls at different time points in one complete ECG cycle (denoted by red dots).  The 
left ventricular wall (LVW) is shown at the top of the image, followed by the septum (SEP) in 
the middle and the right ventricular wall (RVW) at the bottom. Cumulative strains are 













Figure 2.6: Heterogeneous strain distributions occur at the right ventricular apex - Spatial 
distribution of (A) incremental strains during systole and (B) cumulative radial strains near the 
beginning of diastole, showing a transition in strain magnitude near the RVA (circled in red), 
over a short distance compared to a similar transition over the cardiac apex. Black outlines (A) 
are used to identify regions used for whole-wall strain analysis. Black squares (B) are used to 













Figure 2.7: Quantification of incremental and cumulative strains in the canine Heart 1 - 
Incremental (A) and cumulative (B) strains within canine Heart 1 during systole (S, 0-310 ms) 
and diastole (D, 310-595 ms). Sustained, elevated strains are observed within the right ventricle 
(RV) as compared to the left ventricle (LV) during systole. Mid-wall incremental strains (C) and 
end-systolic mid-wall cumulative strains (D) show elevated RV strains compared to LV strains. 













Figure 2.8: Quantification of incremental and cumulative strains in the canine Heart 2 - 
Incremental (A) and cumulative (B) strains within canine Heart 2 during systole (S, 0-290 ms) 
and diastole (D, 290-645 ms). Sustained, elevated strains are observed within the right ventricle 
(RV) as compared to the left ventricle (LV) during systole. Mid-wall incremental strains (C) and 
end-systolic mid-wall cumulative strains (D) show elevated RV strains compared to LV strains. 











Figure 2.7: Healthy bovine hearts exhibit fatty deposits along the triangle of dysplasia  - Intact 
bovine heart. Note the significant fatty deposit around the superior circumference of the heart, 
some mild fatty streaks following the left-anterior descending coronary artery, and notably, the 




















2.6 – Appendix 
 
%Select grid points left to right, up to down 
%image should be 16bit format through ImageJ 
%Image should be preferably around 2.5 MB 
  
image = uigetfile; 
imagedata = imread(image); 
imagedata = uint16(imagedata); 
  
  
H = input('How Many Cells in the Y Direction?'); 
W = input('How Many Cells in the X Direction?'); 
  




for j = 1:floor(ny./H)-1:((H-1)*(floor(ny./H))); 
     
    for k = 1:floor(nx./W)-1:((W-1)*(floor(nx./W))); 
         
        image1=imagedata([j:(j+(ny./H))],[k:(k+(nx./W))]); 
        imshow(image1,'InitialMagnification','fit'); 
        O(i,:) = ginput(1); 
        P(i,:) = ginput(1); 
        i=i+1; 
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Characterizing the Mechanical and Signaling Properties of 
Cardiac Myocytes Expressing ARVC-Causing Plakoglobin 
 
 
3.1 – Introduction 
 More than half of ARVC patients exhibit one or more mutations in genes encoding 
desmosomal proteins.1  This has led many investigators to suggest that ARVC is a “disease of 
the desmosome” in which defective cell-cell adhesion plays a critical pathogenic role.  In support 
of this widely held hypothesis are electron microscopy studies of patient endomyocardial 
biopsies and mouse models of human disease showing decreased numbers of desmosomes in 
ventricular myocardium and apparent clefts or widening of various components within the 
intercalated disk.2-4  Delmar and associates have shown that knockdown of plakophilin-2 in 
neonatal rat cardiac myocytes in vitro greatly reduces cell-cell adhesion strength,5 and we have 
previously shown that, when expressed in HEK cells, mutant forms of plakoglobin linked to 
ARVC can alter cell stiffness or cause a similar marked loss of cell-cell adhesion strength.6  
There is also clinical evidence implicating abnormal biomechanical factors in ARVC.  For 
example, recent findings have revealed that ARVC progression may be exacerbated by strenuous 
exercise.7 Additional motivation comes from our findings presented in Chapter 2, where we 
show that the right ventricular (RV) apex, an area preferentially affected in ARVC, exhibits 
diminished junctional plakoglobin localization and elevated incremental strains.8 Noting that the 
function of desmosomes is to provide tissues with their mechanical strength, regions of 
diminished plakoglobin expression may have weakened tissue cohesion, potentially creating a 
mechanically weak spot in the heart. Furthermore, ARVC may be part of a cardiocutaneous 
syndrome in which the skin phenotype appears to be directly related to mechanical stress.  One 




the palms and soles arising after birth once these regions are subjected to mechanical stresses 
during normal daily activities.  However, while these observations all suggest that mechanical 
stress plays a critical role in promoting the ARVC phenotype, the underlying mechanisms remain 
poorly defined and there is no direct evidence of weakened cell-cell adhesion in the hearts of 
patients with ARVC.   
 Previous studies of mechanotransduction in cardiac myocytes have characterized 
responses of monolayers of cultured myocytes to stretch, but responses to shear stress may also 
be particularly pertinent.9-11  In vivo, cardiac myocytes are organized into a laminar sheet-like 
architecture with loose collagenous coupling between sheets.  Relative movement of these 
laminar sheets during the cardiac cycle may cause direct shearing between adjacent sheets or 
shear from interstitial fluid motion.12, 13 Canine studies, for example, have identified myocardial 
shear as a significant factor in wall thickening.14, 15 Additionally, short-term fluid shear stresses 
of 90 to 600 mdyn/ cm2 regulate expression of a wide variety of cardiac markers in rat cardiac 
myocytes, including the contractile proteins α-sarcomeric actin and troponin-T, the gap junction 
protein connexin43 (Cx43), and the cell-cell adhesion protein N-cadherin without affecting 
phosphorylation of p38, an established marker of cell apoptosis.16, 17  In particular, regulation of 
cell-cell adhesion proteins may play an important role in ARVC pathogenesis, contributing to the 
adhesion defects often associated with this condition. To gain greater insights into potential 
mechanisms by which desmosomal mutations cause ARVC, we characterized biomechanical 
properties and responses to shear stress in neonatal rat ventricular myocytes expressing two 
distinct mutant forms of the desmosomal protein plakoglobin which have been linked to ARVC 
in patients.  We used atomic force microscopy to measure cell stiffness. Although several 
techniques exist to measure the elasticity of cells (i.e. – magnetic twisting cytometry,18 
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micropipette aspiration,19 microindentation,20-22 etc.), atomic force microscopy (AFM) is the 
most widely applied, reliable technique with the least potential for damaging the cells being 
studied. Using AFM, we show that the cardiac myocytes expressing ARVC-causing mutant 
plakoglobin exhibit no significant changes in cell-cell stiffness. Furthermore, our initial 
investigation into cell-cell adhesion (using aggregate assays) showed no significant differences 
in cells expressing mutant plakoglobin, relative to control cells. Because defective intercellular 
adhesion is widely believed to play a role in ARVC pathogenesis, we decided to confirm our 
findings with dispase assays (which also showed no differences in cell-cell adhesion strength).  
Changes in mechanotransduction may also contribute to ARVC pathogenesis. 
Specifically, changes at the molecular level may compound any changes in adhesion that occur 
form the expression of mutant plakoglobin. Therefore, in addition to examining cell-cell 
adhesion, we investigate changes in junctional protein distribution, apoptosis, and ERK 
phosphorylation. We determined that cells expressing mutant plakoglobin were unable to 
remodel plakoglobin, as well as N-cadherin, at cell-cell junctions, suggesting mutant plakoglobin 
expression can destabilize both desmosomal and non-desmosomal junctions. With cell death 
being a hallmark characteristic of ARVC, we performed TUNEL assays to show that mutant 
plakoglobin expression led to an increase in apoptosis. We also investigate ERK 
phosphorylation, which is involved in hypertrophic response in cardiac myocytes, and is 
responsive to shear stress.16 Cardiac myocytes can respond to increased mechanical loading by 
undergoing hypertrophy, and desmosomal integrity has been shown to affect the hypertrophic 
response in cardiac myocytes.23, 24 Despite the belief that ARVC-causing mutations result in 
desmosomal destabilization, we show that ERK phosphorylation is not disrupted by the 
expression of ARVC-causing plakoglobin. Finally, we perform pharmacological interrogation to 
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restore the wild-type phenotype in our disease model.  Overall, we observed no differences in 
biomechanical properties.  Instead, myocytes expressing mutant plakoglobin exhibited abnormal 
responses to mechanical stress that were corrected by SB216763, which is a well-documented 
inhibitor of GSK3β.25-28 
 
3.2 – Methods 
3.2.1 – Cell Culture and Transfection 
  Primary cultures of neonatal rat myocyte cultures (NRVM) were prepared from ventricles 
of 1-day old Wistar rat pups (Charles River, Indianapolis) as previously described.29 Hearts from 
10 neonatal rats were removed and finely minced. The pieces were serially digested in a 
dissociation solution (Ca2+/Mg2+-free Hanks balanced salt solution, GIBCO) containing 0.1% 
trypsin, 60 μg/ml pancreatin (Sigma, MO), 20 units/ml penicillin and 20 μg/ml streptomycin. 
Cells were seeded at a density of 310K cells/cm2. NRVM were cultured on collagen-coated glass 
slides in M199 media (Life Technologies, NY) supplemented with 5% fetal calf serum (Sigma, 
MO) and 100 µM BRDU (Sigma, MO).  After 2 days in culture (or immediately following 
isolation for cell aggregate cultures), cells were exposed for 1 hour at 37 oC to adenoviruses 
containing wild-type human plakoglobin, or plakoglobin constructs with either the S39_K40insS 
mutation (linked to autosomal dominant ARVC) or the 2057del2 mutation (linked to Naxos 
disease).  Cells transfected with virus containing wild-type plakoglobin were used to control for 
viral transfection and possible effects related to over-expression.  Adenovirus containing green 
fluorescent protein (GFP) was used to monitor transfection efficiency. Viruses were obtained 
through a collaboration with the Saffitz Lab at Beth Israel Deaconess Medical Center (Boston, 
MA). The wild-type plakoglobin construct and both mutant forms of plakoglobin included a V5 
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epitope tag to facilitate exogenous protein identification by immunostaining and 
immunoblotting.  Recombinant adenoviral constructs were created using the ViraPower 
Adenoviral Expression system (Invitrogen) using a pAd/CMV/V5-DEST vector through LR 
clonase-mediated recombination. Experiments were performed 24 hours after adenoviral 
transfection. All animal work was performed in accordance with the Institutional Animal Care 
and Use Committee of Columbia University. 
 
3.2.2 – Cell-Cell Adhesion Assays 
  Cell-cell adhesion strength was measured using dispase assays and cell aggregate assays. 
Dispase assays were performed using monolayers of transfected NRVM on collagen-coated glass 
chamber slides.  Monolayers were pre-treated with 10 µM blebbistatin for 20 minutes to 
minimize contractions, followed by a solution containing 2.4 U/mL dispase and 10 µM 
blebbistatin for 30 minutes at 37 oC and 1% CO2. Intact cell sheets that had lifted off the culture 
dish were agitated for 3 min in a rotary shaker at 70 rpm, and the number of fragments was 
quantified using ImageJ.5, 6  To further validate the dispase assays, additional studies were 
performed in monolayers of NRVM treated with 1 µM cytochalasin-D for 1 hour (post-lift), or in 
non-transfected monolayers exposed to a specific siRNA against plakoglobin or N-cadherin, as 
previously described,30 to compare effects on adhesion strength caused by desmosomal protein 
knockdown versus expression of mutant desmosomal proteins.  Non-targeting siRNA was used 
to control for the effects of the transfection process. As both adenoviral and siRNA treatments 
are forms of transfection, in this study we restrict our use of the term ‘transfection’ to refer to 
adenoviral transfection, and ‘knockdown’ to refer to siRNA transfection. Cell aggregate assays, a 
commonly used assay for studying cell-cell adhesion, were performed by seeding 20 µL hanging 
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drops of culture media with 10,000 cardiac myocytes.  Three days later, cell aggregates were 
agitated by pipetting, and the number of resulting fragments was quantified using integrated 
morphometry analysis in Metamorph. 
 
3.2.3 – Immunoblotting 
  Immunoblotting was performed as previously described.30 Cultured NRVM were lysed in 
standard RIPA lysis buffer containing 500 nM phenylmethanesulfonyl fluoride, 50 mM sodium 
fluoride, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, and protease inhibitor 
cocktail.  Samples were solubilized in LDS sample buffer supplemented with 5% v/v 2-
mercaptoethanol. Total protein concentration was determined by Bradford assay (Sigma).  
Soluble fractions containing equal amounts of total protein were separated using SDS 
polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Millipore, MA).  
Immunoblotting was performed using the following mouse anti-human antibodies: anti-
plakoglobin (Sigma 1:2000), anti-phosphorylated ERK1/2 (Cell Signaling 1:1000), anti-total 
ERK1/2 (Cell Signaling 1:1000), anti-Rnd1 (Santa-Cruz Biotechnology 1:200), anti-Isg15 
(Santa-Cruz Biotechnology 1:200)  and horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (Biorad 1:1000).  Blots were developed with ECL reagents (Perkin Elmer, 
MA) and imaged using a FUJI imaging unit (Fujifilm, CT).  Relative band intensities were 
quantified using ImageJ, with values normalized to loading controls (total-ERK 1/2 for 
phosphorylated-ERK 1/2). 
 
3.2.4 – Atomic Force Microscopy 
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  Atomic force microscopy (AFM) was performed using a BioScope Catalyst AFM 
mounted on an Olympus IX-81 inverted light microscope (Olympus, PA).  A silicon-nitride DNP 
probe (Bruker, CA) was used to characterize the stiffness of control myocytes and cells 
expressing mutant forms of plakoglobin.  Indentations of 400 nm were made on the surface of 
the cells. The elastic modulus was determined using the force (calculated as a product of the 
cantilever’s spring constant and tip deflection), and the deflection vs. displacement data fit to an 
eighth-order polynomial, as previously described.31, 32 Readings were acquired between 
consecutive contractions (which were easily visible on the AFM real-time readout) without 
further treatment.  Five measurements from each cell were acquired and averaged to yield 
‘whole-cell’ stiffness. 
 
3.2.5 – Shear Flow 
  NRVM were sheared under oscillatory flow conditions in a parallel-plate shear chamber 
at 0.06 Pascal (Pa) for 4 hours at 37oC.  Thereafter, the cells were either immunostained for 
plakoglobin/N-cadherin or lysed for immunoblotting measurements of plakoglobin, V5, and 
phosphorylated or total ERK.  The shear level was estimated by (1) using a parallel plate model 
to simulate the shear induced by adjacent myocardial sheets,17 and (2) using a range of shear 
stresses that have been previously shown to induce ERK phosphorylation without activation of 
the p38 pathway.16 The formula used to calculate the shear level was derived by applying a force 
balance to incremental unit of fluid, and solving for the shear stress at the walls of two parallel 
plates (Figure 3.1). The relationship was derived as follows: 
 
𝑃(𝑑𝑥 𝑑𝑧) − (𝑃 +
𝜕𝑃
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By solving for 
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, and applying the boundary condition 𝑉 (𝑦 =  
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) = 0, we can determine the 
velocity profile within the parallel plate: 
 
















, we can determine our relationship for applied shear stress: 
 













where 𝜏𝑤𝑎𝑙𝑙 represents the shear stress applied to our cells (0.06 Pa), Q represents the fluid flow 
rate into the chamber, μ represents the fluid viscosity (6.5 x 10-4 Ns/m2), and H and D the 
dimensions of the parallel plate chamber. By designing the chamber to have a channel height of 
H = 7.87 x 10-4 m, a depth of D = 12.7 x 10-3 m, we can determine the fluid flow rate necessary 
to apply a peak shear stress of 0.06 Pa (Figure 3.2). Oscillatory shear stress (sinusoidal 
waveform; 1Hz peak to peak) was applied to the cells by using syringes (Hamilton, NV; #81020 
1710TLL 100uL SYR) connected to the shear chamber with silicone tubing (Instech, PA; 
#P625/10K.093) to create fluid flow through the chamber.  
Minimal shear control experiments were performed by shearing untransfected myocytes 
at the lowest possible shear setting to ensure that media was refreshed above the cell monolayer, 
but at flow rates well below reported response shear stress levels (≤ 0.01 Pa).  In some 
experiments, cells were incubated with SB216763 (5 µM) for 24 hours before shearing and 
throughout the duration of shear to determine if this compound, identified in a previous chemical 
58 
 
screen in a zebrafish model of ARVC,11 could reverse changes in cell mechanical and 
mechanotransduction properties caused by expression of mutant plakoglobin. 
 
3.2.6 – Immunofluorescence 
  NRVM were immunostained based on established protocols.33 Cells were simultaneously 
blocked and permeabilized for 45 minutes in 3% normal goat serum, 1% w/v BSA, and 0.15% 
Triton X-100 in PBS, followed by an overnight incubation at 4oC with either mouse-monoclonal 
anti-plakoglobin (Sigma; 1:1500 in blocking buffer) or anti-N-cadherin (Sigma; 1:1500) 
antibodies.  Samples were then incubated with secondary antibody (Invitrogen; 1:1500) for 2 
hours at room temperature.  The immunostained preparations were imaged at 40x (1.3 NA) using 
an Olympus IX-81 inverted confocal microscope.  Each image was subsequently masked to 
isolate cell junctions, allowing for discrete quantification of junctional immunoreactive signal.  
Images were analyzed using quantitative confocal microscopy as previously described.6, 34 Each 
image was masked to isolate cell junctions, allowing for discrete quantification of junctional 
immunoreactive signal. Using ImageJ, the same threshold was applied to each image. The 
fraction of junctional pixels above threshold was calculated by dividing the number of pixels 
above threshold by the total number of pixels in the image. 
 
3.2.7 – Apoptosis Assay 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were 
performed using an in situ cell death detection kit (Roche Diagnostics, Basel, Switzerland) as 
previously described.30 Adherent cells were fixed in 4% paraformaldehyde for 1 hour at room 
temperature, permeabilized with 0.1% Triton X-100 for 2 minutes on ice, and then incubated in 
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50μL of TUNEL reaction mixture at 37 oC for one hour in the dark. Samples were analyzed 
directly using fluorescence microscopy. 
 
3.2.8 – RNA Isolation and Microarray Analysis 
 Total RNA was isolated from neonatal rat ventricular myocytes using the Qiagen RNeasy 
Kit according to the manufacturer’s recommended protocol. Cells were cultured and transfected 
to express NX plakoglobin as described in Methods Section 3.2.1. Shear assays were performed 
24 hours after adenoviral transfection, using time-matched controls. For SB216763-treated cases, 
cells were exposed to the drug immediately after transfection. All samples were lysed in parallel 
using 350 µL of RLT buffer. Lysates were passed through the RNeasy spin columns to capture 
the RNA. Following two washes with 500 µL of RPE buffer, RNA was eluted in 50 µL of 
RNase-free water. RNA concentration was measured using a Nanodrop spectrophotometer 
(Thermo Scientific), and samples were sent to the Yale Center for Genome Analysis for 
processing using the Affymetrix Rat ST 2.0 gene array.   
 
3.2.9 – Statistical Analysis 
 Data sets with more than 3 independent groups were analyzed using the non-parametric 
Kruskal-Wallis analysis of variance (ANOVA) test in Prism. Data showing significance (p ≤ 
0.05) were further analyzed using Dunn’s post hoc test for multiple comparisons. For data sets 
involving fewer than 3 independent groups, data were analyzed using the Mann-Whitney test. 
Differences were considered to be statistically significant and indicated with * when p ≤ 0.05 or 




3.3 – Results 
3.3.1 – Expression of ARVC-Causing Mutant Plakoglobin in Cardiac Myocytes 
  Immunostaining with an antibody against the V5 epitope tag in myocytes transfected to 
express epitope-tagged wild-type (WT PG), Naxos (2057del2 PG) or S39_K40insS (InsS PG) 
confirmed the localization of exogenous plakoglobin at cell junctions, and in the case of 
2057del2 PG transfected cells, also within the nucleus (Figure 3.3A). Only background levels of 
signal were seen in non-transfected control cells (Figure 3.3A). Immunostaining with an 
antibody against an N-terminal epitope in plakoglobin showed a similar pattern of signal 
distribution (Figure 3.3B).  Quantification of immunoblots of transfected cardiac myocyte lysates 
with an anti-plakoglobin antibody confirmed expression of exogenous plakoglobin at levels 
comparable to that of the endogenous protein (Figure 3.3C). All lysates contained endogenous 
plakoglobin, while lysates from WT PG and InsS PG transfected myocytes also showed a 
second, more slowly migrating band corresponding to the exogenous form of plakoglobin 
containing the V5 tag. As expected, the 2057del2 PG protein was smaller than the endogenous 
protein because the Naxos mutation results in a premature stop codon and truncation of the C-
terminus. Transfection with a GFP virus confirmed >90 percent viral efficiency, and was used to 
determine the multiplicity of infection for the WT, InsS and NX viral constructs (Figure 3.3D). 
 
3.3.2 – Cell-Cell Adhesion Strength and Stiffness Unaffected by Mutant Plakoglobin Expression  
Dispase assays were used to determine whether expression of mutant desmosomal 
proteins affected the strength of cell-cell adhesion. Aggregate assays were used to confirm the 
findings of the dispase assay.  As shown in Figure 2A and B, the number of fragments resulting 
from mechanical agitation of monolayers in the dispase assay (Figure 3.4A) or cell clusters in the 
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cell aggregate assay (Figure 3.4B) or was not significantly different among the control myocytes 
and myocytes expressing either mutant form of plakoglobin. As a control experiment to 
determine if the dispase assay was sensitive enough to detect changes in cell-cell adhesion, 
control monolayers were exposed to 1 µM cytochalasin-D and then lifted from the culture dish 
and subjected to rotary agitation.  As shown in Figure 3.4C, treatment with cytochalasin-D 
caused 3.0- and 3.5-fold increases in monolayer fragmentation after 1 and 3 minutes of agitation, 
respectively, thus providing independent confirmation that the dispase assay sensitively detects 
changes in cell-cell adhesion strength.   
 The apparent lack of effect of mutant plakoglobin on adhesion is different than previous 
studies5 reporting reduced adhesion in cardiac myocytes following siRNA knockdown of 
expression of the desmosomal protein plakophilin-2 in which dominant mutations are often 
found in ARVC patients.  To determine whether the effects on cell adhesion are different 
following knockdown of a desmosomal protein versus expression of a disease-causing mutation, 
we treated non-transfected myocytes with two different specific siRNAs against plakoglobin.  As 
shown in Figure 3.4D, treated cells exhibited a marked reduction in plakoglobin expression.  
Both siRNAs led to between 2.0- and 2.7-fold increases in monolayer fragmentation relative to 
time-matched controls after 1 or 3 minutes of agitation, whereas treatment with a negative 
siRNA had no effect on cell-cell adhesion. Knockdown efficiency was quantified by western 
blot. TUNEL assays were used to exclude reduced cell viability as a possible cause of increased 
sheet fragmentation (3.4E). Suppression of N-cadherin showed a similar reduction in cell-cell 
adhesion strength, suggesting this effect is not limited to the suppression of desmosomal 
proteins, but other adhesion proteins as well (Figure 3.4F). Taken together, these results indicate 
that expression of exogenous plakoglobin at levels comparable to that of the endogenous protein 
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does not significantly affect cell-cell adhesion strength, whereas knockdown of the endogenous 
protein has a marked effect in reducing adhesion.   
  
3.3.3 – Shear Stress Induces Junctional Plakoglobin and N-Cadherin Remodeling 
 A custom oscillatory shear device and parallel plate flow chamber were used to shear 
control and transfected myocytes.  In response to oscillatory fluid shear at 0.06 Pa, control and 
WT PG transfected myocytes exhibited between 2.3 and 3.3-fold increases in immunoreactive 
signal for junctional plakoglobin (Figure 3.5A and B) compared to unsheared cells. In contrast, 
myocytes expressing the 2057del2 PG or InsS PG mutants failed to increase junctional 
plakoglobin signal following shear.  A considerable amount of the plakoglobin in myocytes 
expressing the 2057del2 PG mutation was distributed within cells in a distinct perinuclear 
pattern, but there was little if any change in either the amount or distribution of plakoglobin 
signal in response to shear. To determine whether SB216763 could restore the control-level 
response to shear in cells expressing mutant plakoglobin, we repeated experiments in cultures 
exposed to 5 µM SB216763 for 24 hours.  As shown in Figures 3.5C, cells expressing either InsS 
PG, 2057del2 PG, or 1851del123 PKP exhibited robust increases in junctional signal for 
plakoglobin in response to oscillatory shear equivalent to the response in control cells and cells 
expressing wild-type proteins (2.0-, 2.2-, and 2.6-fold increases in 2057del2 PG, InsS PG and 
1851del123 PKP cells, respectively).  Neither shear stimulation nor treatment with SB216763 
altered the overall expression of plakoglobin in WT and Naxos cells (Figure 3.5D). Thus, failure 
to increase junctional signal for plakoglobin in response to shear can be normalized by 
SB216763 in cells expressing mutant plakoglobin without alter plakoglobin expression levels.    
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 Control and WT PG cells also showed 2- and 1.6-fold increases in junctional signal for 
N-cadherin, respectively, following oscillatory shear (Figure 3.6A-B).  In contrast, cells 
expressing either mutant form of plakoglobin failed to increase junctional N-cadherin signal in 
response to shear (Figure 3.6A-B).  As was seen for plakoglobin, SB216763 restored the ability 
of cells expressing mutant plakoglobin to increase junctional N-cadherin signal in response to 
shear (Figure 3.6C; 1.9- and 1.7-fold increases in 2057del2 PG and InsS PG cells, respectively, 
compared with 1.6- and 2.1-fold increases in control  and WT PG cells).   
 In view of the increased signals for junctional plakoglobin and N-cadherin in control and 
WT PG cells following shear, we repeated studies of cell mechanical properties to determine if 
there was a correlation between the amount of junctional protein signals and measures of cell-
cell adhesion strength.  As shown in Figure 3.6D, there was no significant change in cell-cell 
adhesion strength following shear in control myocytes or myocytes expressing mutant 
plakoglobin.  Thus, within the limits of these assays, there appears to be no apparent relationship 
between the amount of junctional immunoreactive signals for plakoglobin or N-cadherin and 
cell-cell adhesion. 
 We next used AFM to measure cell stiffness.35  Whereas our previous studies have shown 
a change in cell stiffness in HEK epithelial cells expressing the InsS PG (but not the 2057del2 
PG) mutation in plakoglobin,6 we found no such change in stiffness in cardiac myocytes 
expressing either mutant form of plakoglobin (Figure 3.6E). 
 




Apoptosis is increased in the myocardium of patients with ARVC,36 and myocytes expressing the 
2057del2 PG mutant form of plakoglobin exhibit increased apoptosis rates under basal condition 
with even greater apoptosis in response to cyclical stretch.11  To determine if a similar response 
occurs in oscillatory shear, we measured apoptosis by TUNEL assays.  As shown in Figure 3.7A, 
myocytes expressing 2057del2 PG showed elevated levels of apoptosis in response to shear 
stress, relative to unsheared cells. In contrast, myocytes expressing the InsS PG variant of 
plakoglobin exhibited no changes in apoptosis with exposure to oscillatory shear, although the 
mean level of apoptosis was elevated relative to control cells. Treatment with SB216763 returned 
apoptosis levels to control levels in myocytes expressing 2057del2 PG (Figure 3.7B).     
 We next assessed whether ERK phosphorylation may be disrupted by ARVC mutant 
plakoglobin. Immunoblotting performed on myocytes exposed to oscillatory shear flow 
confirmed an increase in the amount of phosphorylated ERK (p-ERK) in response to shear for 
control and WT PG myocytes, as well as cells expressing mutant forms of plakoglobin (Figure 
3.7C). After 10 minutes, control, WT PG, 2057del2 PG and insS PG transfected myocytes 
exposed to oscillatory shear exhibited 3.3-, 3.2-, 4.2-, and 3.5-fold increases in p-ERK relative to 
unsheared controls, respectively. 
 
3.3.5 – SB216763, But Not GSK3 Knockdown, Rescues Wild-Type Phenotype 
 Treatment with SB216763 was able to recover the wild-type phenotype in cells 
expressing ARVC-causing mutant plakoglobin. SB216763 selectively inhibits glycogen synthase 
kinase-3 (GSK3) by competitively binding to the GSK3 ATP-binding site, and it has been shown 
to have protective effects in a variety of cell types.11, 37-40 To determine if GSK3 inhibition was 
the mechanism by which cells expressing mutant plakoglobin recovered the wild-type 
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phenotype, we treated WT, InsS and NX transfected myocytes with a specific siRNA against 
GSK3, and exposed the cells to shear stress. SiRNA-mediated suppression of GSK3 did not 
recapitulate the effects of SB216763 treatment. Junctional remodeling was unaffected in WT 
cells, exhibiting 2.7- and 2.0-fold increases in junctional plakoglobin signal is response to shear 
stress relative to unsheared controls following treatment with non-targeting or GSK3 siRNA, 
respectively (Figure 3.8A-B). InsS and NX cells did not recover the ability to remodel cell 
junctions following GSK3 siRNA treatment (Figure 3.8B).  
While the reported function of SB216763 is to selectively inhibit GSK3, suppression of 
GSK3 does not mimic the effects of SB216763, suggesting the compound has a secondary 
function. To gain further insight into the mechanism by which SB216763 is able to restore the 
wild-type phenotype in cells expressing mutant plakoglobin, we performed microarray analysis 
on NX cells treated with SB216763 and exposed to shear stress (Figure 3.8C). Microarray 
analysis revealed >100 genes that were differentially expressed.  Immunoblotting for certain 
gene targets identified in the microarray analysis was performed on WT and NX cells. Targets 
were selected based on the level of differential expression (greater than 2-fold increase and p < 
0.05), and their role in regulating cytoskeletal or junctional protein distribution. As shown in 
Figure 3.8D, neither gene product showed significant differences in expression levels between 
WT and NX cells with SB216763 treatment, although immunoblotting results from NX cells did 
confirm the microarray results.  
    
3.4 – Discussion 
In the broader scope of this thesis, the work in this chapter was meant to assess changes 
in the mechanical and signaling properties of cardiac myocytes expressing ARVC-causing 
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mutant plakoglobin. The key observation from the data presented is that expression of ARVC-
linked mutant plakoglobin in ventricular myocytes in amounts roughly equivalent to that of the 
native protein, has no apparent effect on cell mechanical properties per se (no change in cell 
stiffness or cell-cell adhesion strength) but instead has a marked effect on how cells respond to 
mechanical stimulation.  This is an important distinction that has significant implications about 
how mutations in desmosomal proteins cause the complex disease phenotypes seen in patients 
with ARVC.  It is widely believed that defective intercellular adhesion plays an important 
pathogenic role in ARVC patients with desmosomal mutations, but direct evidence for this 
hypothesis has been lacking.  It has been previously reported that knockdown of desmosomal 
proteins can result in a dramatic decrease in cell-cell adhesion strength.5  To reconcile the 
apparent discrepancy between this observation and the present study, we used two separate 
siRNAs targeting different regions to knock down expression of plakoglobin, and in both cases 
observed a similar marked decrease in cell-cell adhesion strength.  This highlights important 
differences in the pathophysiological consequences of suppression of a desmosomal protein 
versus expression of a mutant form of a desmosomal protein.  In this regard, it appears that 
mutant desmosomal proteins are expressed in the myocardium of patients with ARVC.  This is 
certainly true in Naxos disease which, although inherited as a recessive trait, is not related to loss 
of gene expression but rather to expression of mutant plakoglobin with a gene-dosage effect.  
Indeed, germline deletions of plakoglobin, desmoplakin and plakophilin all cause embryonic 
lethal phenotypes in mice,41-44 providing further evidence that ARVC is related to expression of 
mutant proteins rather than haploinsufficiency.  While it should not be surprising that 
knockdown of a desmosomal gene leads to loss of cell-cell adhesion, our results show that 
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expression of a mutant desmosomal gene has a different effect which is more likely to reflect the 
pathophysiology of the disease in patients.   
 Another interesting related observation from our study is the apparent lack of correlation 
between the amount of immunoreactive signal for plakoglobin at cell-cell junctions and the 
strength of cell-cell adhesion. While there is likely a positive correlation between desmosome 
number and immunoreactive signal intensity, many factors (i.e. - variations in antibody binding 
specificity, macromolecular crowding, and epitope accessibility) can make the exact relationship 
difficult to determine. Our data are consistent with the idea that redistribution of plakoglobin 
from junctional to intracellular/intranuclear sites, a feature seen in both patients and experimental 
models of ARVC, has no major effect on cell-cell adhesion strength but rather leads to abnormal 
responses to mechanical stimuli that appear to be a fundamental part of the disease pathway in 
ARVC.  Finally, we have previously reported that when HEK cells overexpress the 2057del2 PG 
mutation, there is a marked reduction in cell-cell adhesion strength without a change in cell 
stiffness, whereas overexpression of the InsS PG mutation in HEK cells has the opposite effects. 
The discrepancy between previous results and those presented in this study may result from 
differences in cell type, and the disparate roles of desmosomes in cardiac myocytes and HEK 
cells. It is possible that the robust actin-myosin network present in cardiac myocytes, but not in 
HEK cells, may mask any minor alterations in cell stiffness that result from the expression of 
mutant desmosomal proteins. The results of the present study reinforce the important idea that 
epithelial cells are not necessarily good surrogates for cardiac myocytes, and changes in HEK 
cells expressing cardiomyopathy-related disease mutations must be interpreted with caution.   
The lack of differences in cell-cell adhesion between control and myocytes expressing 
mutant plakoglobin motivated our search for a molecular mechanism underlying the 
68 
 
pathogenesis of ARVC. Thus, we chose to investigate (1) ERK phosphorylation, a documented 
promoter of myocyte hypertrophy in vitro and in vivo,16, 45, 46 and (2) apoptosis.  While ERK 
phosphorylation (before and after shear) remained unaffected by the expression of ARVC-
causing mutant plakoglobin, apoptosis was elevated in myocytes expressing 2057del2 PG. 
Cardiac myocytes have been shown to undergo hypertrophy as a response increased mechanical 
loading in order to restore wall stresses to normal levels.47-49 Cell-cell adhesion defects are often 
associated with ARVC-pathogenesis, so it was surprising that ERK phosphorylation, the short-
term response to stimuli, was unaltered in cells expressing ARVC-causing mutant proteins. We 
expect that defects in cell-cell adhesion would alter the stress/strain balance on the myocardium, 
with cardiac myocytes responding by undergoing sustained hypertrophy (to compensate for 
decreased force generation). Our findings support the hypothesis that apoptosis, and not cell-cell 
adhesion, likely play a more significant role in ARVC pathogenesis. Noting the nuclear 
localization of plakoglobin in these cells, elevated levels of apoptosis is consistent with work by 
Garcia-Gras et al that suggests nuclear localization of plakoglobin can recapitulate the ARVC 
phenotype (i.e. – adipogenesis, fibrogenesis, and myocyte apoptosis).50 
 Treatment of myocytes expressing mutant plakoglobin with SB216763 attenuated 
apoptosis back to control levels in myocytes expressing the 2057del2 PG and InsS PG mutations. 
Furthermore, SB216763 treatment recovered junctional remodeling of plakoglobin and N-
cadherin in cells expressing 2057del2 PG, InsS PG mutant proteins. The fact that SB216763 was 
able to alter the subcellular distribution of plakoglobin without changing the level at which the 
protein is expressed further supports the hypothesis SB216763 corrects underlying defects in 
protein trafficking.11 Attenuation of apoptosis may be explained by a decrease in the suppression 
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of canonical wnt/beta-catenin signaling by nuclear plakoglobin, as evidenced by the loss of the 
nuclear localization of plakoglobin. 
SiRNA-mediated suppression of GSK3 in myocytes expressing ARVC-causing mutant 
proteins did not recover the wild-type ability to increase junctional plakoglobin signal in 
response to shear stress. Although SB216763 is a well-documented inhibitor of GSK3,25-28 these 
data suggest that additional mechanisms may be involved in the recovery of the wild-type 
phenotype in InsS and NX cells. The inability for GSK3 suppression to recapitulate the wild-type 
phenotype motivated our search for a molecular mechanism. Interestingly, treatment with SB2, 
exposure to shear stress, and a combination of both treatments all caused a number of genes to be 
differentially expressed in NX cells. We identified two key differentially expressed genes 
associated with cytoskeletal remodeling (Rnd1) and protein transport (Isg15), and performed 
immunoblotting to determine if the expression of these genes was altered in NX cells, relative to 
WT cells. Although no significant differences in Rnd1 or Isg15 expression were observed 
between NX and WT cells following treatment with SB216763, the microarray analysis did 
identify several other interesting targets (associated with Rho GTPase signaling, protein 
shuttling, and cytoskeletal remodeling). Further investigation is necessary to elucidate the exact 
mechanism by which SB216763 restores the wild-type phenotype. 
 We conclude that ARVC-causing mutations in plakoglobin lead to altered cellular 
distribution of plakoglobin and N-cadherin, as well as increased apoptosis in NX cells, without 






3.5 – Figures 
 
Figure 3.1 – Diagram of shear flow device and force balance: (Left) Diagram showing the 
dimensions of the shear flow chamber, where ‘H’ represents the vertical distance between the 
two parallel plates and ‘D’ represents the depth of the chamber normal to the direction of flow. 
(Right) Force balance on an incremental block of fluid used to derive the relationship between 











Figure 3.2 – Media flow rate is directly proportional to applied shear stress: As derived in section 
3.2.5, the derived expression to calculate applied shear stress is directly proportional to the flow 
rate of media through the shear chamber. As determined above using Matlab, to achieve a 
physiologically relevant shear stress level of 0.06 pascals, we flow media in the chamber at a rate 

























Figure 3.3 – ARVC models express transgenic plakoglobin at endogenous levels: (A) V5 
immunostaining of control (non-transfected) myocytes (C) and myocytes transfected to express 
wild-type plakoglobin (WT PG), S39_K40insS (InsS PG), or 2057del2 PG.  No signal is seen in 
non-transfected control cells (thus demonstrating absence of non-specific binding). Normal 
junctional localization of V5 labeled protein is seen in cells transfected to express WT PG, InsS 
PG and 2057del2 PG mutants.   Cells transfected with 2057del2 PG also show nuclear 
localization of truncated 2057del2 plakoglobin.  (B) Immunostaining with an anti-plakoglobin 
antibody against an N-terminal epitope (which recognizes both endogenous and transfected 
forms of WT PG, InsS PG and 2057del2 PG) shows a similar pattern.   (C)  Immunoblot (left) 
using an N-terminal anti-plakoglobin antibody, with quantification (right) showing roughly 
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equivalent amounts of endogenous plakoglobin and transgene plakoglobin in WT PG, InsS PG 
and 2057del2 PG cells (n=4).  While the control lane shows a single band corresponding to 
endogenous plakoglobin, the WT PG, InsS PG, and 2057del2 PG lanes exhibit a second band, 
corresponding to the transgenic plakoglobin. The larger molecular weight of transgenic 
plakoglobin observed in the WT PG and InsS PG lanes is explained by the addition of a C-
terminal V5 tag, connected using a linker peptide. The lower molecular weight transgenic 
plakoglobin band observed in the 2057del2 PG lane is explained by the truncation of the C-
terminal end of plakoglobin – a result of the premature stop codon generated by the frame-shift 
2057del2 mutation. (D) Quantification of cells transfected with a GFP virus to confirm 98.9 ± 











Figure 3.4 - Cell-cell adhesion strength and cell stiffness are unaffected by mutant plakoglobin:  
(A) Quantification of control and mutant plakoglobin-transfected cardiac myocyte monolayer 
fragmentation in dispase assays before and after 1 or 3 minutes of agitation. Cardiac myocytes 
expressing mutant plakoglobin show no differences in cell-cell adhesion relative to WT PG 
(n=5).  (B) Quantification of cluster sizes in control and transfected cardiac myocytes in cell 
aggregate assays (n=3). Cardiac myocyte aggregates expressing mutant plakoglobin show no 
differences in aggregate fragmentation relative to WT PG. (C) Dispase assays in normal (non-
transfected) cardiac myocytes showing significant reduction in cell-cell adhesion in cells 
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exposed to 1uM cytochalasin-D (n=5). (D) Dispase assays in normal (non-transfected) cardiac 
myocytes showing significant reduction in cell-cell adhesion in cells following siRNA knock-
down of endogenous plakoglobin (n=5).  Plakoglobin knock-down was confirmed by 
immunoblotting (inset), and quantified (right). (E) Quantification of apoptosis (percent TUNEL-
positive nuclei) in control (C) cells transfected with non-targeting siRNA, or siRNA targeting 
plakoglobin (n=6). Mechanical shear caused cells to shear off the glass slide, preventing 
quantification. (F) Dispase assays in normal (non-transfected) cardiac myocytes showing 
significant reduction in cell-cell adhesion in cells following siRNA knock-down of endogenous 
N-cadherin (Nc) (n=6).  N-cadherin knock-down was confirmed by immunoblotting (inset), and 








Figure 3.5 – Shear-induced plakoglobin remodeling is reversibly altered in ARVC: (A) Immuno-
fluorescence images showing the distribution of plakoglobin (N-terminal antibody) in control (C) 
and transfected cardiac myocytes before (top) and after (middle) exposure to shear, and after 
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treatment with SB216763 (SB2; bottom).  Control and WT PG cells show increased 
immunoreactive signal with junctional localization after shear, whereas cells expressing InsS PG 
or 2057del2 PG show no apparent increase in junctional signal after shear.  Treatment with the 
drug restored the normal shear-induced increase in junctional signal in cells expressing mutant 
plakoglobin or plakophilin. (B) Quantification of junctional plakoglobin signal before and after 
shear in cells transfected to express mutant plakoglobin (n=5). (C) Quantification of junctional 
plakoglobin signal before and after shear in cells transfected to express mutant plakoglobin and 
treated with SB216763 (n=6). (D) Immunoblot (left and middle) and quantification of 
immunoblots (right) using a N-terminal anti-plakoglobin antibody showing no overt changes in 
plakoglobin levels in cells expressing WT or 2057del2 PG (n=5) in response to shear or 







Figure 3.6 - Shear-induced N-cadherin remodeling is reversibly altered in ARVC: (A) N-
cadherin immunofluorescence images showing the distribution of N-cadherin in control (C) and 
transfected cardiac myocytes before (top) and after (middle) exposure to shear, and after 
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treatment with SB216763 (bottom).  As seen in Figure 3, control (non-transfected) cells and cells 
transfected to express wild-type plakoglobin (WT PG) show increased junctional signal for N-
cadherin after shear, whereas no shear-induced increase was seen in cells expressing mutant 
forms of plakoglobin.  Treatment with the drug restored the normal shear-induced increase in 
junctional signal in cells expressing mutant plakoglobin. (B) Quantification of junctional N-
cadherin signal before and after shear (n=5). (C) Quantification of junctional N-cadherin signal 
before and after shear in cardiac myocytes treated with SB216763 (n=5).  SB216763 restored the 
normal shear-induced increase in junctional N-cadherin signal.  (D) Dispase assay measurements 
in control cells (C) and cells expressing transgenic plakoglobin after exposure to mechanical 
shear stress (n=5).  Cardiac myocytes expressing mutant plakoglobin show no differences in cell-
cell adhesion as compared to control cells. (E) Cell stiffness measurements in control cells (C) 
and cells expressing wild type or mutant plakoglobin before and after exposure to mechanical 
shear stress (n=4).  Cardiac myocytes expressing mutant plakoglobin show no differences in cell 




























Figure 3.7 - Cell viability, but not ERK phosphorylation, is altered by mutant plakoglobin 
expression: (A) Quantification of apoptosis (percent TUNEL-positive nuclei) in control (C) cells 
and cells transfected to express wild-type or mutant forms of plakoglobin before and after 
exposure to shear (n=4).  Mechanical shear stress caused an increase in apoptosis in cells 
expressing 2057del2 PG.  (B)  Quantification of apoptosis (percent TUNEL-positive nuclei) in 
cells treated with SB216763 (SB2) before and after shear (n=3).  SB216763 prevented the shear-
induced increase in apoptosis in cells expressing 2057del2 PG.  (C) Representative immunoblot 
and quantitative data showing equivalent levels of phospho-ERK activation (P-ERK), with total 
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ERK (T-ERK) as a loading control, in control cells (C) or cells transfected to express wild-type 






















Figure 3.8 - GSK3 Suppression Does Not Mimic the Effects of SB216763: (A-B) Quantification 
of junctional plakoglobin signal before and after shear in cells treated with (A) non-targeting 
(n=3) or (B) GSK3 siRNA (n=3).  Knockdown of GSK3 did not restore the normal shear-
induced increase in junctional signal in cells expressing InsS or NX plakoglobin. (C) Scatter 
plots from microarray data analysis showing differential gene expression when comparing NX 
cells exposed to shear stress, treated with SB216763, or both (n=3). (D) Immunoblots using anti-
Rnd1 (top), anti-Isg15 (middle) or anti-GAPDH (bottom) antibodies in WT and NX cells 
exposed to shear stress, treated with SB216763, or both. Isg15 and Rnd1 were targets identified 
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Different ARVC-Causing Proteins Produce Similar Changes 
to Cell Properties 
 
 
4.1 – Introduction 
 The identification of defective molecular mechanisms that are common across ARVC-
patients remains a strategic area of research. Specifically, recent studies have investigated the 
mechanistic basis for different ARVC-causing mutations in hopes of identifying common defects 
in a signaling pathway – information that could be used to develop diagnostic tests or identify 
therapeutic targets.1-3 For example, it has been hypothesized that mutations in genes encoding 
desmosomal proteins could destabilize desmosomal junctions, leading to the hallmark features of 
ARVC such as arrhythmia (via disruption of gap junctions) or apoptosis (via suppression of Wnt 
signaling by nuclear plakoglobin).1, 3 While our findings in chapter 3 support this hypothesis, it 
remains to be seen if this defective phenotype is also present in cells expressing other, more 
common disease-causing mutant desmosomal genes (such as plakophilin). 
 In chapter 3, we showed that the expression of ARVC-causing mutations in plakoglobin 
can reversibly alter the cell’s ability to remodel cell-cell junctions in response to shear stress, 
without significantly affecting cell-cell adhesion or stiffness. In order to determine if these 
features are common among cells expressing different mutant desmosomal genes, we 
investigated the mechanical and signaling properties of cardiac myocytes expressing mutations 
in plakophilin - the most commonly mutated gene in ARVC patients.4-6 Key features of mutant 
plakophilin-2 mediated ARVC pathogenesis include the intrinsic instability of the protein, and 
resulting disruption of desmosomal formation, but how these features might affect the cell’s 
ability to alter the junctional distribution of plakophilin in response to mechanical loading has 




is central feature ARVC pathogenesis,1, 8 but whether mutant plakophilin-2 expression can also 
alter the cellular distribution of plakoglobin remains to be seen. We hypothesize that the 
expression of ARVC-linked mutant plakophilin-2 alters the cellular distributions of both 
plakophilin-2 and plakoglobin, without changes in biomechanical properties.  
In order to gain insight into plakophilin-2-mediated ARVC pathogenesis, we 
characterized biomechanical properties and responses to shear stress in neonatal rat ventricular 
myocytes expressing a mutant form of plakophilin-2. In studying the response to shear stress, we 
specifically focused on cell junctions where plakophilin-2 is a binding partner. In addition to 
repeating key assays performed in chapter 3 in cells expressing mutant plakophilin-2 (i.e. – 
dispase assays, TUNEL stains, and atomic force microscopy), we also investigate the 
hierarchical effects of plakoglobin or plakophilin suppression on desmosomal destabilization (i.e. 
- the ability of mutant plakophilin-2 to regulate junctional plakoglobin localization, and vice 
versa). Finally, to determine if mutant desmosomal proteins participate in the mechanism by 
which SB216763 can restore the wild-type phenotype, we compare the effects of mutant protein 
expression and siRNA-mediated suppression on junctional remodeling in cells treated with 
SB216763.  
Similar to cells expressing ARVC-causing plakoglobin, mutant plakophilin-2 expression 
altered the cell’s ability to remodel plakophilin-2 at cell-cell junctions in response to shear stress, 
without affecting cell-cell adhesion or stiffness. Interestingly, the expression of mutant 
plakophilin also altered the junctional localization of plakoglobin as well (a feature not seen in 
cells expressing mutant plakoglobin). Suppression of plakophilin-2 mimicked the effects of 
mutant plakophilin-2 expression (i.e. – treated cells were unable to increase the immunoreactive 
signal for plakoglobin in response to shear stress), although SB216763 treatment did not restore 
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the wild-type phenotype in these cells. Finally, we show that treatment with SB216763, but not 
siRNA mediated GSK3 inhibition, was able to restore the wild-type phenotype in cells 
expressing mutant plakophilin-2. 
 
4.2 – Methods 
4.2.1 – Cell Culture and Transfection 
  Primary cultures of neonatal rat myocyte cultures (NRVM) were prepared from ventricles 
of 1-day old Wistar rat pups (Charles River, Indianapolis) as previously described.9 Hearts from 
10 neonatal rats were removed and finely minced. The pieces were serially digested in a 
dissociation solution (Ca2+/Mg2+-free Hanks balanced salt solution, GIBCO) containing 0.1% 
trypsin, 60 μg/ml pancreatin (Sigma, MO), 20 units/ml penicillin and 20 μg/ml streptomycin. 
NRVM were cultured on collagen-coated glass slides in M199 media (Life Technologies, NY) 
supplemented with 5% fetal calf serum (Sigma, MO) and 100 µM BRDU (Sigma, MO).  After 2 
days in culture (or immediately following isolation for cell aggregate cultures), cells were 
exposed for 1 hour at 37 oC to adenoviruses containing wild-type human plakophilin-2, or a 
plakophilin-2 construct with the 1851del123 mutation (deletion of exon 10 linked to ARVC). 
 Adenoviral constructs were created using Gateway® Technology with Clonase® II from 
Invitrogen. The wild-type plakophilin-2, mutant plakophilin-2, and eGFP entry clones were 
developed by performing a BP recombination reaction between attB-flanked plakophilin-2 or 
eGFP DNA fragments and an attP-containing pDONR™ 221 vector. The attB-flanked DNA 
fragments were generated using the following primers (5’→3’)_with an attB-KOZAK-overhang:  
 




Reverse primer for wild-type plakophilin-2 – 
GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCTTTAAGAGAGTGGTAGGCTTTGGC 
 
Reverse primer for mutant plakophilin-2 –  
GGGGACCACTTTGTACAAGAAAGCTGGGTGTCTTCCTCCCATCGGGCCAG 
Forward primer for eGFP – 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGCCACCATGGTGAGCAAGGGC 
Reverse primer for eGFP – 
GGGGACCACTTTGTACAAGAAAGCTGGGTGTCTAGATCCGGTGGATCCCGG 
 
 Following the BP recombination reaction, the entry clone reaction products were 
amplified using DH5α chemically competent cells (New England Biolabs) and purified using the 
Qiaprep Spin Mini-prep kit (Qiagen) according to the manufacturer’s recommended protocol. 
The entry clones were sequenced to verify that the PCR and BP recombination reaction steps had 
not introduced any point mutations (insert sequences can be found in Appendix 4.6), and an LR 
recombination reaction was performed to transfer the genes of interest into an attR-containing 
pAd/CMV/V5/DEST adenoviral destination vector. The destination vectors were subsequently 
amplified, sequenced, and sent to Vector Biolabs (Philadelphia, PA) for packaging, amplification 
and titration. The titers for the wild-type plakophilin-2, mutant plakophilin-2 and eGFP 
adenoviruses were 4.4x1010, 3.5x1010, and 3.6x1010 PFU/mL. Cells transfected with virus 
containing wild-type plakophilin-2 were used to control for viral transfection and possible effects 
related to over-expression.  Adenovirus containing green fluorescent protein (eGFP) was used to 
monitor transfection efficiency.  The wild-type plakoglobin construct and both mutant forms of 
plakoglobin included a linker (40 amino acids) and V5 epitope tag to facilitate exogenous protein 
identification by immunostaining and immunoblotting.  Experiments were performed 24 hours 
after adenoviral transfection. All animal work was performed in accordance with NIH guidelines 




4.2.2 – Cell-Cell Adhesion Assays 
 Cell-cell adhesion strength was measured using dispase assays. Dispase assays were 
performed using monolayers of transfected NRVM on collagen-coated glass chamber slides.  
Monolayers were pre-treated with 10 µM blebbistatin for 20 minutes to minimize contractions, 
followed by a solution containing 2.4 U/mL dispase and 10 µM blebbistatin for 30 minutes at 37 
oC and 1% CO2. Intact cell sheets that had lifted off the culture dish were agitated for 20 min in 
a rotary shaker at 70 rpm, and the number of fragments was quantified using ImageJ.10, 11  To 
further validate the dispase assays, additional studies were performed in non-transfected 
monolayers exposed to either of two specific siRNAs against plakophilin-2, as previously 
described,12 to compare effects on adhesion strength caused by plakoglobin knockdown versus 
expression of mutant plakoglobin.  
 
4.2.3 – Immunoblotting 
 Immunoblotting was performed as previously described.12 Cultured NRVM were lysed in 
standard RIPA lysis buffer containing 500 nM phenylmethanesulfonyl fluoride, 50 mM sodium 
fluoride, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, and protease inhibitor 
cocktail.  Samples were solubilized in LDS sample buffer supplemented with 5% v/v 2-
mercaptoethanol. Total protein concentration was determined by Bradford assay (Sigma).  
Soluble fractions containing equal amounts of total protein were separated using SDS 
polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Millipore, MA).  
Immunoblotting was performed using the following antibodies: mouse anti-V5 (Invitrogen 
1:1000), mouse anti-plakophilin-2 (Fitzgerald 1:20), mouse anti-GAPDH (Novus Biologicals 
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1:2000), rabbit anti-GSK3 (Cell Signalling 1:2000) and horseradish peroxidase-conjugated 
secondary antibody (Biorad 1:1000).  Blots were developed with ECL reagents (Perkin Elmer, 
MA) and imaged using a FUJI imaging unit (Fujifilm, CT).  Relative band intensities were 
quantified using ImageJ, with values normalized to loading controls. 
 
4.2.4 – Shear Flow 
 NRVM were sheared under oscillatory flow conditions in a parallel-plate shear chamber 
at 0.06 Pascal (Pa) for 4 hours at 37oC.  Thereafter, the cells were either immunostained for 
plakoglobin/N-cadherin or lysed for immunoblotting measurements of plakoglobin, V5, and 
phosphorylated or total ERK.  The shear level was estimated by (1) using a parallel plate model 
to simulate the shear induced by adjacent myocardial sheets,13 and (2) using a range of shear 
stresses that have been previously shown to induce ERK phosphorylation without activation of 
the p38 pathway.14 The derivation of the formula used to calculate the shear level may be found 
in the methods of Chapter 3, Section 2.5. To investigate the ability of SB216763 to restore the 
wild-type phenotype in cells transfected to express mutant plakophilin-2 or treated with specific 
siRNA against plakoglobin or plakophilin-2, cells were incubated with SB216763 (5 µM) for 24 
hours before shearing and throughout the duration of shear. Suppression of GSK3 with siRNA 
was used to determine if recovery of the wild-type phenotype in cells expressing mutant 
plakophilin-2 was dependent on SB216763-mediated inhibition of GSK3.  
 
4.2.5 – Immunofluorescence 
  NRVM were immunostained based on established protocols.15 Cells were simultaneously 
blocked and permeabilized for 45 minutes in 3% normal goat serum, 1% w/v BSA, and 0.15% 
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Triton X-100 in PBS, followed by an overnight incubation at 4oC with either mouse-monoclonal 
anti-plakophilin-2 (Fitzgerald; 1:20) or anti-plakoglobin (Sigma; 1:1500 in blocking buffer) 
antibodies.  Samples were then incubated with secondary antibody (Invitrogen; 1:1500) for 2 
hours at room temperature.  The immunostained preparations were imaged at 40x (1.3 NA) using 
an Olympus IX-81 inverted confocal microscope.  Each image was subsequently masked to 
isolate cell junctions, allowing for discrete quantification of junctional immunoreactive signal.  
Images were analyzed using quantitative confocal microscopy as previously described.10, 16 Each 
image was masked to isolate cell junctions, allowing for discrete quantification of junctional 
immunoreactive signal. Using ImageJ, the same threshold was applied to each image. The 
fraction of junctional pixels above threshold was calculated by dividing the number of pixels 
above threshold by the total number of pixels in the image. 
 
4.2.6 – Apoptosis Assay 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were 
performed using an in situ cell death detection kit (Roche Diagnostics, Basel, Switzerland) as 
previously described.12 Adherent cells were fixed in 4% paraformaldehyde for 1 hour at room 
temperature, permeabilized with 0.1% Triton X-100 for 2 minutes on ice, and then incubated in 
50μL of TUNEL reaction mixture at 37 oC for one hour in the dark. Samples were analyzed 
directly using fluorescence microscopy. 
 
4.2.7 – Statistical Analysis 
Data sets were analyzed using the non-parametric Kruskal-Wallis analysis of variance 
(ANOVA) test in Prism. Data showing significance (p ≤ 0.05) were further analyzed using 
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Dunn’s post hoc test for multiple comparisons. Differences were considered to be statistically 
significant and indicated with * when p ≤ 0.05 or ** when p ≤ 0.01. Error bars are plotted as the 
standard deviation of the data. 
 
4.3 – Results 
4.3.1 – Expression of ARVC-Causing Mutant Plakophilin-2 in Cardiac Myocytes 
 Immunostaining with an antibody against the V5 epitope tag in non-transfected (control), 
wild-type (WT PKP), and mutant plakophilin-2 (1851del123 PKP) transfected myocytes 
confirmed the localization of exogenous plakophilin-2 at cell junctions in WT PKP cells, but not 
1851del123 PKP cells (Figure 4.1A). Only background levels of signal were seen in non-
transfected control cells. Immunostaining with an antibody against a C-terminal epitope in 
plakophilin-2 confirmed junctional localization of plakophilin-2 in all cases (Figure 4.1B). 
Immunoblotting of untransfected and transfected cardiac myocyte lysates with an anti-V5 
antibody confirmed expression of exogenous plakophilin-2 in both the WT PKP and 1851del123 
PKP cells (Figure 4.1C). Immunoblotting with a C-terminal antibody against plakophilin-2 
(which tags both the exogenous and endogenous forms), normalized to GAPDH, was used to 
confirm that transfection did not result in overexpression of the exogenous protein (Figure 4.1C). 
Due to the relatively similar size of exogenous and endogenous proteins, immunoblotting with 
the C-terminal plakophilin-2 antibody did not show two discrete bands, although  comparison of 
immunostains using antibodies against C-terminal PKP2 and V5 suggests the exogenous wild-
type and mutant proteins are being expressed (but not overexpressed, as evidenced by the 
relatively similar intensity of bands when immunoblotting with the C-terminal PKP2 antibody). 
Transfection with a GFP virus exhibited 97.9 ± 0.2 percent viral efficiency, and was used to 
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determine the multiplicity of infection for the WT PKP and 1851del123 PKP viral constructs 
(Figure 4.1D). 
 
4.3.2 – Cell-Cell Adhesion Strength and Stiffness Unaffected by Mutant Plakophilin-2 
Expression 
 Dispase assays were used to determine whether expression of mutant plakophilin-2 
affected the strength of cell-cell adhesion.  As shown in Figure 4.2A, the number of fragments 
resulting from mechanical agitation of monolayers in the dispase assay was not significantly 
different among the control myocytes and myocytes expressing mutant plakophilin-2. To 
determine whether the effects on cell adhesion are different following knockdown of a 
desmosomal protein versus expression of a disease-causing mutation, we treated non-transfected 
myocytes with either of two specific siRNAs against plakoglobin.  As shown in Figure 4.2B, 
treated cells exhibited a marked reduction in plakophilin-2 expression. Cells treated with either 
of two specific siRNAs against plakophilin-2 showed between 1.9- and 3.5-fold increases in 
monolayer fragmentation relative to time-matched controls after 1 or 3 minutes of agitation 
(Figure 4.2B, left), whereas treatment with a negative siRNA had no effect on cell-cell adhesion. 
Taken together, these results indicate that expression of mutant forms of plakophilin-2 does not 
affect cell-cell adhesion strength, whereas knockdown of the endogenous protein has a marked 
effect in reducing adhesion. Knockdown efficiency was quantified by western blot (Figure 4.2B, 
right), and a TUNEL assay was used to exclude reduced cell viability as a possible cause of 
increased sheet fragmentation (Figure 4.2C).  
 Previous studies, in addition to our work in chapter 3, have shown that different 
mutations can exhibit changes in cell stiffness.10 We next used AFM to measure cell stiffness.17  
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Similar to our results in Chapter 3, we found no changes in stiffness in cardiac myocytes 
expressing mutant plakophilin-2 (Figure 4.2D). 
 
4.3.3 – Shear Stress Induces Junctional Plakophilin-2 and Plakoglobin Remodeling 
 In response to oscillatory fluid shear at 0.06 Pa, control and WT PKP transfected 
myocytes exhibited 2.9- and 3-fold increases in immunoreactive signal for junctional 
plakophilin-2 (Figure 4.3A and B) compared to unsheared cells.  In contrast, myocytes 
expressing the 1851del123 form of plakophilin-2 failed to increase junctional plakophilin-2 
signal following shear.  To determine whether SB216763 could restore the control-level response 
to shear in cells expressing mutant plakophilin-2, we repeated experiments in cultures exposed to 
SB216763 for 24 hours.  As shown in Figure 4.3C, cells expressing the 1851del123 variant of 
plakophilin-2 exhibited a robust increase in junctional signal for plakophilin-2 in response to 
oscillatory shear equivalent to the response in controls and WT PKP cells (3.5-fold increase in 
1851del123 cells compared with 3.2- and 2.1-fold increases in control and WT PKP cells).  
 Cells expressing mutant plakophilin-2 did not exhibit significant remodeling of 
plakoglobin at cell junctions.  Control and WT PKP transfected myocytes exhibited 4- and 2-fold 
increases in immunoreactive signal for junctional plakoglobin (Figure 4.3D) compared to 
unsheared cells, while 1851del123 PKP cells were unable to increase the immunoreactive signal 
for junctional plakoglobin. Treatment with SB216763 recovered the wild-type phenotype; cells 
expressing the 1851del123 variant of plakophilin-2 exhibited 2.7-fold increases in junctional 
signal for plakoglobin in response to oscillatory shear (Figure 4.3E). Surprisingly, junctional 




4.3.4 – Plakophilin Knockdown Alters Plakoglobin Remodeling, But Not Vice Versa 
 To better understand the mechanism by which mutant desmosomal proteins can alter 
junctional remodeling, we treated cells with siRNA to suppress either plakoglobin or plakophilin 
and immunostained for plakophilin or plakoglobin, respectively. In each case, application of 
shear stress to cells where either plakoglobin or plakophilin was suppressed led to a large 
number of cells being sheared away (>50%). The remaining cells, dispersed across the slide in 
small groups (~10-15 cells), maintained enough cell-cell contact for quantification, which was 
performed following mechanical stimulation. Similar to cells expressing mutant plakoglobin, 
suppression of plakoglobin did not alter junctional plakophilin remodeling (Figure 4.4A-B). 
Cells treated with siRNA to suppress plakophilin did not exhibit a significant increase in 
junctional plakoglobin in response to shear stress, and treatment with SB216763 was unable to 
recover the wild-type phenotype in these cells (Figure 4.4C-D).  
 
4.3.5 – SB216763, But Not GSK3 Knockdown, Rescues Wild-Type Phenotype 
 To determine if GSK3 inhibition was the mechanism by which SB216763 restored the 
wild-type phenotype, cells transfected with WT PKP or 1851del123 PKP were exposed to shear 
stress following siRNA-mediated suppression of GSK3. In response to shear stress, WT PKP 
transfected myocytes exhibited 2.2- and 2.3-fold increases in immunoreactive signal for 
junctional plakoglobin with and without GSK3 siRNA treatment, respectively, compared to 
unsheared cells (Figure 4.5). In contrast, cells transfected with 1851del123 PKP did not recover 
the ability to increase junctional immunoreactive signal in response to shear stress following 




4.4 – Discussion 
 One key finding in this chapter is that cells expressing mutant plakophilin-2 respond 
abnormally to shear stress without changes in biomechanical properties (i.e. - cell-cell adhesion 
and stiffness). Another, arguably more significant finding, was that the expression of mutant 
plakophilin-2 altered the junctional remodeling of both plakophilin-2 as well as plakoglobin in 
response to shear stress, making defective plakoglobin trafficking a common phenotype in cells 
expressing different ARVC-causing mutant desmosomal proteins. Interestingly, while the 
expression of mutant plakophilin was able to alter plakoglobin trafficking, there was asymmetry 
with respect to the expression of mutant plakoglobin being able to alter the cellular distribution 
of plakophin-2. Although we show that desmosomal protein suppression can mimic the effects of 
mutant protein expression in certain aspects (i.e. – junctional remodeling), protein suppression 
does not fully recapitulate the disease phenotype (i.e. – mutant protein expression is required for 
SB216763 to restore the wild-type phenotype). Finally, we reaffirm our findings in chapter 3, 
that GSK3 inhibition does not recapitulate the effects of SB216763, particularly in cells 
expressing mutant plakophilin-2. 
 In Chapter 3 we showed, despite the belief that defective intracellular adhesion plays a 
pathogenic role in ARVC, that the expression of ARVC-causing plakoglobin has no significant 
effect on cell-cell adhesion strength in vitro. Our findings in this chapter, namely that lack of 
adhesion differences between cells expressing mutant plakophilin-2 and control cells, reinforce 
our hypothesis that adhesion defects are secondary, if they exist at all, to abnormal cellular 
response to certain mechanical stresses in ARVC pathogenesis. Consistent with our previous 
findings, siRNA-mediated suppression of plakophilin-2 significantly decreased cell-cell adhesion 
strength. These data highlight the differences between suppression of a desmosomal protein 
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versus expression of a mutant form of a desmosomal protein, where the latter likely reflects the 
pathophysiology of the disease in patients. 
 Immunostaining revealed that the expression of mutant plakophilin-2 was able to alter the 
junctional localization of both plakophilin-2 as well as plakoglobin, while the expression of 
mutant plakoglobin only altered the cellular distribution of plakoglobin. This is a significant 
finding as it identifies, for the first time, a shear-stimulated signaling defect common across cells 
expressing different disease-causing desmosomal proteins. Although follow-up work is 
necessary to determine if all ARVC-causing mutations alter plakoglobin trafficking, our data 
suggest that the cellular redistribution of plakoglobin likely plays a critical pathogenic role. To 
further investigate how plakophilin-2 altered junctional plakoglobin distribution, we treated cells 
with siRNA to suppress plakophilin-2, and immunostained for plakoglobin. Although 
suppression of plakophilin-2 altered the junctional localization of plakoglobin in response to a 
shear stimulus, SB216763 treatment was unable to recover the wild-type phenotype. These data 
provide further evidence that mutant protein expression, and not suppression, is necessary to 
recapitulate the disease phenotype.  
 Treatment with SB216763 was able restore the junctional remodeling of both 
plakophilin-2 and plakoglobin in cells expressing mutant plakophilin-2. Together with our 
findings in chapter 3, these data provide supporting evidence for the ‘final common pathway’ 
hypothesis. Although SB216763 is advertised as a GSK3 inhibitor, siRNA-mediated GSK3 
suppression was unable to recapitulate the effects of SB216763. It is likely that in addition to 
inhibiting GSK3, SB216763 also has secondary effects, which are not recapitulated by siRNA-




 We conclude that ARVC-causing mutations in plakophilin lead to altered cellular 























4.5 – Figures 
 
 
Figure 4.1 – ARVC models express transgenic plakophilin: (A) V5 Stain on control (C), wild-
type plakophilin (WT PKP), and mutant plakophilin (1851del123 PKP) transfected myocytes.  
Normal junctional localization is seen in WT PKP transfected cells. No junctional signal is 
observed in cells expressing 1851del123 PKP. (B) Immunostaining with an anti-plakophilin-2 
antibody against a C-terminal epitope (which recognizes both endogenous and transfected forms 
of WT PKP and 1851del123 PKP. (C) Immunoblots using anti-V5 (top), anti-C-terminal 
plakophilin (middle) and anti-GAPDH (bottom) antibodies. V5 bands in the WT PKP and 
1851del123 PKP lysates confirm successful transfection. The relatively similar size between 
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exogenous and endogenous plakophilin prevented detection of discrete bands using the anti-C-
terminal plakophilin antibody. (D) Quantification of cells transfected with a GFP virus to 

















Figure 4.2 - Cell-cell adhesion strength and stiffness are unaffected by mutant plakophilin 
expression: (A) Quantification of control and mutant plakophilin transfected cardiac myocyte 
monolayer fragmentation in dispase assays before and after 1 or 3 minutes of agitation. Similar 
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to myocytes expressing mutant plakoglobin, cardiac myocytes expressing mutant plakophilin-2 
(n=6) also show no differences in cell-cell adhesion relative to WT PKP (n=4), suggesting the 
effect does not depend on which desmosomal protein is being mutated. (B) Dispase assays in 
normal (non-transfected) cardiac myocytes showing significant reduction in cell-cell adhesion in 
cells following siRNA knock-down of endogenous plakophilin-2 (n=5).  Plakophilin-2 knock-
down was confirmed by immunoblotting (inset), and quantified (right). (C) Quantification of 
apoptosis (percent TUNEL-positive nuclei) in control cells transfected with non-targeting 
siRNA, or siRNA targeting plakophilin (n=6). (D) Cell stiffness measurements in control cells 
(C) and cells expressing wild type or mutant plakophilin before and after exposure to mechanical 
shear stress (n=3).  Cardiac myocytes expressing mutant plakophilin show no differences in cell 

















Figure 4.3 – Shear-induced plakoglobin and plakophilin localization are reversibly altered in 
pkp-model ARVC cells: (A) Immunofluorescence images showing the distribution of plakophilin 
(C-terminal antibody) in control (C) and transfected cardiac myocytes before (top) and after 
(middle) exposure to shear, and after treatment with SB216763 (SB2; bottom).  Control and WT 
PKP cells show increased immunoreactive signal with junctional localization after shear, 
whereas cells expressing 1851del123 PKP show no apparent increase in junctional signal after 
shear.  Treatment with the drug restored the normal shear-induced increase of in junctional signal 
in cells expressing mutant plakophilin. (B-C) Quantification of junctional plakophilin signal 
before and after shear in (B) untreated (n=3) or (C) SB216763 treated (n=3) cells transfected 
with wild-type or mutant plakophilin.  (D-E) Quantification of junctional plakoglobin signal 
before and after shear in (D) untreated (n=4) or (E) SB216763 treated (n=4) cells transfected 
with wild-type or mutant plakophilin. (F-G) Quantification of junctional plakophilin signal 
before and after shear in (F) untreated (n=3) or (G) SB216763 treated (n=3) cells transfected 







Figure 4.4 – Plakophilin Knockdown Alters Plakoglobin Remodeling, But Not Vice Versa: (A-
B) Quantification of junctional plakophilin signal before and after shear in (B) untreated (n=3) or 
(C) SB216763 treated (n=3) cells where plakoglobin has been suppressed. (C-D) Quantification 
of junctional plakoglobin signal before and after shear in (B) untreated (n=3) or (C) SB216763 








Figure 4.5 - SB216763 treatment, but not GSK3 suppression, rescues wild-type phenotype: 
Quantification of junctional plakoglobin signal before and after shear in non-targeting siRNA 
treated (n=3) or GSK3 siRNA treated (n=3) cells transfected with wild-type or mutant 
plakophilin. Suppression of GSK3 siRNA did not mimic the effects of SB216763. Suppression 
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5.1 – Summary 
 The goal of this dissertation was to provide insight into the effects of ARVC-causing 
mutant proteins on the mechanical and signaling properties of cardiac myocytes. To that end, we 
began by employing histological techniques and elastography to first characterize the structural 
and mechanical properties of the healthy right ventricular myocardium, in hopes of identifying 
features that would make the right ventricle susceptible to ARVC pathogenesis. We next moved 
to an in vitro disease model to investigate the effects of ARVC-causing desmosomal protein 
expression at the cellular level. Specifically, we used adenoviral infection to express ARVC-
causing mutant plakoglobin in neonatal rat ventricular myocytes, and performed a variety of 
assays to measure changes in cell-cell adhesion, cell stiffness, subcellular protein distribution, 
apoptosis, and ERK phosphorylation (an upstream marker of cardiac hypertrophy). Finally, to 
identify common mechanical or signaling defects in cells expressing different mutant 
desmosomal proteins, we repeated key assays previously performed in cells expressing mutant 
plakoglobin, but now in cells expressing mutant plakophilin-2. The following is a brief summary 
of the major findings: 
 
1. The right ventricular apex exhibits cardiac fiber disarray and diminished junctional 
protein localization. 
2. Elastography data revealed persistent, elevated strains in the right ventricle, and 




3. Expression of ARVC-linked mutant plakoglobin and plakophilin-2 did not alter cell 
biomechanical properties, including cell-cell adhesion and cell stiffness 
4. Suppression of desmosomal proteins did not recapitulate the ARVC phenotype with 
respect to changes in cell-cell adhesion strength and junctional protein remodeling, 
highlighting the differences in the pathophysiological consequences of suppression of a 
desmosomal protein versus expression of a mutant form of a desmosomal protein. 
5. Expression of either mutant plakoglobin or plakophilin reversibly altered the junctional 
localization of plakoglobin in response to shear stress. Only the mutant plakophilin (not 
mutant plakoglobin) expression altered the junctional localization of plakophilin. 
Treatment with SB216763 was able to recover the wild-type phenotype. 
6. SiRNA mediated suppression of plakophilin altered the junctional remodeling of 
plakoglobin, but not vice versa. 
 
5.2 – Limitations 
 There are several limitations to consider with respect to work presented in this 
dissertation. Although rats do not naturally suffer from ARVC, we chose to study fiber disarray 
in this species because their cardiac physiology exhibits a striking similarity to that of humans 
(i.e. – a four-chambered heart that pumps blood throughout the circulatory system). Several 
studies have also confirmed that artificial induction of a desmosomal gene mutation thought to 
cause ARVC in humans can result in an ARVC-like phenotype in rats. The use of Eulerian-based 
incremental strains was necessitated by the elastography acquisition approach. Further work 
using multiple angles of approach, in addition to a larger sample size of hearts that are co-
analyzed using elastography and processed for staining, will permit the extraction of three-
dimensional strain data and allow a more in depth analysis to support these preliminary findings. 
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Additionally, close examination of the three-dimensional strains around the RVA in particular 
may be helpful in more precisely characterizing the strain magnitudes and spatial distributions of 
such strains that may provide more insight into the structure-function relationship of this region. 
The cell-cell adhesion data presented in Chapters 3 & 4 do not necessarily represent in 
vivo tissue cohesion, particularly because neonatal cells do not possess the anisotropic 
characteristics of adult myocytes, which may affect cell-cell adhesion. However, it was 
unexpected, given all the previous work, that there was no significant alteration in cell-cell 
adhesion. While shear responses are consistent with ARVC, we do not claim that ARVC 
development is attributed primarily to shear response; likely stretch and non-mechanical 
pathways are also involved. 
 We note that the use of viral transduction of mutant plakoglobin and plakophilin did not 
lead to significant overexpression of the exogenous proteins, which increases confidence that our 
results are due to the effects of the transgene and not protein overexpression. Since Naxos 
disease is recessive; it is possible that our model cells express sufficient endogeneous 
plakoglobin to attenuate the effects of the 2057del2 PG mutation. However, plakoglobin re-
distribution to nuclear sites and elevated apoptosis suggest this is not the case, and that Naxos 
disease may be related to the expression of the mutant protein with a gene-dosage effect. 
Furthermore, the insS PG mutation is dominant and no significant biomechanical changes were 
observed, while both mutant plakoglobin and plakophilin variants led to molecular changes. 
Thus we have some confidence that molecular changes likely dominate in the manifestation of 
ARVC. 
 Further investigation is required to determine the exact mechanism of action for 
SB216763. SiRNA-mediated suppression of GSK3 did not recapitulate the effects of SB216763, 
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suggesting the compound either does not inhibit GSK3 (unlikely considering the reported 
function for the compound by the manufacturer, and the numerous publications in which the 
compound is used for GSK3 inhibition), or that the compound has secondary effects.  The 
reported method of inhibition is competitive binding to GSK3’s ATP binding site, without 
altering the expression level of the protein, which prevented the validation of SB216763’s 
function via immunoblotting. Direct validation of GSK3 activity was not feasible as the 
necessary equipment (scintillation counter) was not readily available. Noting that GSK3 
functions in the phosphorylation of β-catenin, GSK3 activity kits typically involve measuring the 
incorporation of radioactively-labeled phosphate groups into substrates of GSK3 with the use of 
a scintillation counter. Microarray analysis performed on cells expressing 2057del2 PG further 
supported the role of SB216763 in having secondary effects on gene expression. Although 
multiple genes were differentially expressed, immunoblotting did not identify differences 
between cells expressing either wild-type or mutant plakoglobin. The analysis of this data is 
admittedly incomplete, requiring further analysis of other gene targets, as well as repeating 
microarray analysis for wild-type cells for a more robust comparison, as well as performing 
analysis across multiple time points.  
It should also be noted that the 1851del123 PKP mutation has not been identified as an 
ARVC-causing mutation, per se. Instead, the mutation results in a deletion of exon 10 in the 
PKP2 gene. Although the sequence to function relationship is not fully understood, the high 
concentration of ARVC-causing mutations found in this region (9 unique mutations in total) 
suggests that result in a similar ARVC-phenotype suggest that the disease may be modeled by 
the deletion of this exon. In fact, cells expressing 1851del123 PKP mimic the effects observed in 
cells expressing ARVC-causing mutant plakoglobin. Although further investigation is necessary, 
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our initial findings support the hypothesis that tertiary structure of plakophilin-2 encoded by 
exon 10 is sensitive to any changes in primary structure. We did not repeat all of the experiments 
using mutant plakophilin-2, because our previous findings suggested that plakoglobin re-
distribution is a key event in the final common disease pathway regardless of the underlying 
pathogenic mutation, and partially because the 1851del123 PKP mutation is not directly linked to 
ARVC cases, but rather a deletion of a region that is prone to ARVC mutation. 
 
5.3 – Future Studies 
 Here we propose several studies that could follow from the findings of this dissertation: 
 
5.3.1 – In Vivo / In Vitro Comparison Study 
Preliminary work has shown that healthy rodents can exhibit exercise-induced changes in 
junctional protein localization (namely plakoglobin). The work in this dissertation has shown 
that the expression of ARVC-causing mutant proteins can alter the cellular distribution of 
plakoglobin in response to mechanical stress. Comparison of in vitro and in vivo data 
investigating the similar mutations would provide further insight into whether or not defective 
plakoglobin trafficking is a conserved phenotype that contributes to ARVC pathogenesis at the 
organism level. Furthermore, these experiments discretely characterize the role of increased 
mechanical stimulation, one of many exercise-induced changes that occur at the organism level, 
in ARVC pathogenesis.  
  
5.3.2 – Determining the mechanism of action for SB216763 
 Further investigation is needed to determine how SB216763 is able to restore the wild-
type phenotype in cells expressing mutant desmosomal proteins. SiRNA-mediated protein 
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expression experiments have confirmed that the mechanism likely includes secondary effects to 
the inhibition of GSK3, and requires the expression of mutant desmosomal proteins (i.e. – 
SB216763 is unable to recover the wild-type phenotype in cells where plakoglobin or 
plakophilin has been suppressed). Preliminary work has shown SB216763 alters the cellular 
expression of connexin-43. Further investigation is necessary to determine the effects of altered 
connexin-43 expression on calcium handling the cardiac action potential, particularly in cells 
expressing arrhythmogenic cardiomyopathy-causing proteins. These experiments would shed 
light on the final common pathway hypothesis, and whether or not SB216763 treatment would 
be effective in treating all ARVC resulting from the expression of different disease-causing 
proteins. 
 
5.3.3 – Mechanical Stimulation of Human iPSC-Derived Models of ARVC 
 The development of platforms for diagnostic testing and pharmacological interrogation 
remains a strategic area of research, and could have a clinical benefit for patients diagnosed with 
ARVC. Specifically, epigenetic modifiers and variable phenotypic expression can often result in 
a higher rate of misdiagnosis. Furthermore, lethal arrhythmias can form well before a patient 
progresses to the overt stages of the disease. It would be interesting to see if mechanical 
stimulation of patient-derived iPSCs could accelerate the disease phenotype in vitro, or mimic 
the effects presented in this dissertation. Furthermore, investigating the effects of acute vs 
chronic stimulation (mimicking moderate and strenuous exercise, respectively) could provide 
inside into the role of exercise in disease pathogenesis. It remains to be seen if modulating the 
intensity (strain magnitude), duration (acute vs. chronic), and frequency of mechanical loading 
can recapitulate late stage disease characteristics in vitro. As more progress is made towards 
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identifying final common disease pathways, in vitro platforms for pharmacological testing will 
become a necessity as more drugs targets are identified (similar to the identification of and 
inhibition of GSK3 using SB216763).  
 
5.4 – Conclusions 
 The data presented here provide significant insight into the structural and mechanical 
properties of the native right ventricular myocardium, as well as the underlying defects that 
contribute to the pathogenesis of ARVC, which is not well understood.   
 Despite the fact that the right ventricular apex is a key site for the development of 
arrhythmias, little investigation has been done into this region of the heart. Our detailed 
characterization of the right ventricular apex revealed key features (i.e. - cardiac fiber disarray, 
diminished junctional protein expression, and elevated / heterogeneous strain distributions) that 
implicate this region as a weak spot in the heart, and motivated our study of the effects of 
ARVC-causing proteins on the redistribution of junctional proteins in response to mechanical 
stress. 
 Defective intercellular adhesion is widely believed to be a pathogenic factor in disease 
progression, but evidence for this hypothesis typically stems from cell and animal models where 
desmosomal proteins have been suppressed. While it should not be surprising that knockdown of 
a desmosomal gene leads to loss of cell-cell adhesion, our results show that expression of a 
mutant desmosomal gene has a different effect which is more likely to reflect the 
pathophysiology of the disease in patients. In particular, the data presented in this dissertation 
shows that the expression of ARVC-linked mutant plakoglobin in ventricular myocytes in 
amounts roughly equivalent to that of the native protein, has no apparent effect on cell 
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mechanical properties (no change in cell stiffness or cell-cell adhesion strength), but instead has 
a marked effect on the cellular response to mechanical shear stress.  
 The identification of defective molecular mechanisms that are common across ARVC-
patients remains a strategic area of research, particularly for the development of diagnostic tests 
or identification of therapeutic targets.5-7 We identify a common signaling defect in cells 
expressing different ARVC-linked mutant proteins; the data presented shows that the cells 
expressing either mutant plakoglobin or mutant plakophilin exhibit an abnormal response to 
mechanical stress. Furthermore, we show that these defects could be corrected with SB216763, 
an annotated inhibitor of GSK3β.25-28  
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